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ABSTRACT 
Bile acids are physiological detergents and surfactants with recently identified 
roles as signaling hormones. Maintenance of physiologically normal bile acids levels 
is fundamentally important as a deregulation within the bile acid synthesis pathway 
has the potential to result in an unbalanced bile acid pool.  This may result in any 
number of pathological down stream effects and can exacerbate various diseases and 
disorders.  Chenodeoxycholic acid (CDCA) and cholic acid (CA) are two major 
primary bile acids in humans with CDCA being more hydrophobic and toxic than CA. 
Aldo-keto reductase 1D1 (AKR1D1) and 12-alpha-hydroxylase (CYP8B1) are the two 
key enzymes responsible for the synthesis of CDCA and CA, respectively.  
It remains largely unknown how AKR1D1 and CYP8B1 are regulated to 
maintain homeostatic CDCA and CA concentrations under physiological conditions. 
Likewise, little is known regarding the regulation of their synthesis under pathological 
conditions, or the mechanisms by which this regulation occurs.  To date, much focus 
has been on CYP8B1 expression as the key regulator of bile acid synthesis, and also as 
the determining factor for the CDCA to CA ratio within the bile acid pool. We 
hypothesize that due to the increased toxicity associated with elevated CDCA 
concentrations, combined the knowledge that CDCA is a potent ligand for various 
signaling pathways, the liver is consistently altering AKR1D1 expression, and not 
CYP8B1, in an effort to maintain physiologically normal liver function.  
Further knowledge pertaining to the regulation of individual primary bile acids 
may shed light on novel mechanisms by which various disorders and diseases, which 
are attributed to bile acid dysregulation, can be treated or prevented.  For example, it 
  
has been established that the CDCA composition of the bile acid pool is lower in 
patients with diabetes; however, the mechanism by which this occurs is unclear. 
Understanding the role of bile acid synthesis in diabetic models may identify a 
mechanism by which CDCA production is being regulated.  Hepatocellular carcinoma 
(HCC) is the most prevalent type of liver cancer.  It has been identified that high 
concentrations of CDCA are toxic to the hepatocytes and can have carcinogenic 
effects; therefore a better elucidation of the regulation of CDCA production may prove 
important for prevention or progression of HCC.  Intrahepatic cholestasis of 
pregnancy (ICP) is a disorder that occurs within the third trimester of pregnancy as a 
result of elevated bile acid levels.  Although AKR1D1 expression is known to increase 
during pregnancy, the role of AKR1D1 in pregnancy has not yet been established.   
Experiments were carried out in-vitro in a human liver carcinoma cell line and 
in-vivo in mice as well as on human liver tissue and tissue sections.  Our data revealed 
that endogenous AKR1D1, and not CYP8B1, is transcriptionally and translationally 
regulated by primary bile acids, CDCA and CA, by a negative feedback or positive 
feed-forward mechanism, respectively.  Likewise, with the use of a human AKR1D1 
promoter reporter, the transcriptional regulation of AKR1D1 expression was 
investigated, and confirmed endogenous results.  Additionally, results indicated that in 
conditions of metabolic disorder, (i.e., diabetes) or in liver cancer, human hepatic 
AKR1D1 expression is significantly decreased as compared to normal human tissue.  
Furthermore, a substantial link was established between AKR1D1 expression, 
estrogen and conditions of ICP in in-vitro and in-vivo experiments.   
  
With knowledge of the cooperative capabilities of primary bile acids on the 
expression of AKR1D1, we next investigated potential signaling pathways involved in 
AKR1D1 regulation.  In-vitro and in-vivo activation of critical bile acid (Farnesoid X 
Receptior, FXR), lipid (peroxisome proliferator activated-receptor, PPAR) and 
cholesterol (Liver X Receptor, LXR) signaling pathways were examined for 
implications on AKR1D1 expression.    Our results demonstrated that while FXR was 
not involved in the regulation of AKR1D1, PPAR activation decreased AKR1D1 
expression and LXR activation resulted in an increase in AKR1D1 expression.  
Furthermore, a substantial link was established between estrogen signaling and 
AKR1D1 expression in-vitro as well as in pregnant mice.   
In conclusion, CDCA and CA are key regulators of AKR1D1, but not 
CYP8B1, expression. Such coordinated down-regulation and up-regulation of 
AKR1D1 by primary bile acids represents a mechanism by which the liver maintains 
homeostatic CDCA and CA levels under physiological condition. The data also 
indicates that LXR and PPAR signaling pathways are involved in regulating AKR1D1 
with the possible identification of response elements in the promoter region. 
Moreover, the data demonstrates that changes to the bile acid composition of diabetic 
patients are due to a down regulation of AKR1D1 resulting in a decreased production 
of CDCA. Our data also demonstrates that in circumstances of HCC, the liver may 
alter bile acid synthesis through the down regulation of AKR1D1 expression, in a 
negative feedback manner to decrease production of CDCA.  Finally, the role of 
AKR1D1 with respect to pregnancy was identified, substantiating a link between 
estrogen and AKR1D1 expression. In summary, our results confirm our hypothesis 
  
that the liver alters AKR1D1 expression in an effort to minimize toxicity associated 
with CDCA production and maintain homeostatic CDCA to CA levels.    
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CHAPTER 1 
INTRODUCTION 
Cholesterol and Bile Acid: 
 Cholesterol is an amphipathic, waxy, fat-like substance that is synthesized 
endogenously by our livers.   It is a fundamental structural component of cell 
membranes as well as a precursor for many intracellular biochemical pathways.  
Cholesterol is found in all animals, and thus, it is in many of the foods that we ingest. 
The liver plays a primary role in not only the digestive and detoxification process but 
also the synthesis of cholesterol and movement of excess cholesterol from the 
bloodstream as required. 
 Bile acids are the end product of cholesterol catabolism. Bile acids are 
produced in the liver and secreted from the hepatocyte into the bile by the membrane-
associated transporter, bile salt export pump (BSEP), and stored in the gallbladder 
(Russell, 2003).  Upon ingestion of a meal, the gallbladder empties the bile into the 
intestinal tract where the bile acids aid in the emulsification and absorption of dietary 
fats and lipids.  Approximately 95% of bile acids are reabsorbed through the upper 
intestines, circulated back to the liver via the portal vein, and then sent back to the 
liver (Russell, 2003).  This transport of conserved bile acid from the intestine to the 
liver is known as enterohepatic circulation, and BSEP is the rate-limiting step. The 
composition of the re-circulating bile acid not only dictate the rate of enterohepatic 
circulation, but also regulate the activation and repression of various signaling 
pathways that range from the regulation of bile acid synthesis to various metabolic 
pathways in the liver, gastrointestinal tract and beyond.   
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 The conversion of cholesterol to bile acids is the primary pathway by which 
cholesterol is removed from the liver (Russell, 2003). There are two types of primary 
bile acids synthesized from cholesterol, cholic acid (CA) synthesized from sterol 12-
alpha hydroxylase (CYP8B1) and chenodeoxycholic acid (CDCA) synthesized from 
aldo-keto reductase 1D1 (AKR1D1) (Russell, 2003). These two bile acids differ 
greatly with respect to their individual roles in cholesterol solubilization and 
absorption. CA is more hydrophilic due to the hydroxylation of the bile acid steroid 
nucleus in the C-12α position and is therefore more efficient in the absorption and 
excretion of cholesterol in the intestine (Chiang, 2009).  CDCA is highly hydrophobic 
and therefore inhibits cholesterol absorption and excretion (Chiang, 2009).  In addition 
to these processes, secondary bile acids are generated by modifications that are carried 
out by intestinal bacteria.  Primary and secondary bile acids can also be further 
conjugated with either glycine or taurine, and this enhances their water solubility. This 
results in 13 total primary and secondary, conjugated and unconjugated bile acids.   
 At physiological concentrations bile acids are not harmful to the body, they are 
essential due to their detergent-like properties, however bile acid accumulation can be 
toxic to hepatocytes.  The hydrophobicity of the bile acid pool contributes to the 
toxicity and thus it is essential to regulate the concentration of individual bile acids 
and the size of the total bile acid pool. The ratio of CA to CDCA concentrations in the 
bile acid pool affects how much cholesterol is absorbed from the food we eat and how 
much is excreted. At physiological concentrations, a 1:1 ratio of CA to CDCA is 
maintained.   A sustained balance of hydrophilic to hydrophobic bile acid is essential 
to support normal, physiologically healthy liver function. The circumstances that can 
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arise due to a deregulation of the CA to CDCA ratio are not restricted to the bile acid 
synthesis pathway.  Due to the signaling characteristic of circulating bile acids, and 
their role as physiological ligands in the activation and suppression of numerous 
pathways, many pathological consequences can occur as a result of a deregulation in 
the CA to CDCA ratio.  Such consequences might include the exacerbation of diabetic 
symptoms, hepatocellular damage or death, or liver tissue inflammation that result in 
cirrhosis, cholestasis, and ultimately, the progression of liver cancer (Perez, 2009). 
The elucidation of the underlying mechanisms by which this bile acid ratio affects the 
progression or exacerbation of such disorders will lead to novel approaches for the 
maintenance of the CA to CDCA ratio of bile acid composition.  Moreover, once the 
mechanistic pathway, through which AKR1D1 and CYP8B1 regulate the production 
of CDCA and CA, respectively, is understood, novel pathways that control the ratio of 
CA to CDCA production will be exposed. These pathways can then be manipulated to 
maintain physiological concentrations in conditions of metabolic disease and distress 
and as a precursor for disease prevention.   
Nuclear Receptors and Bile Acid:  
It is important to note that bile acid signaling is not restricted to the liver. 
Specifically, through enterohepatic circulation, bile acids are circulated from the 
intestines through portal blood back to the liver, and serve as endogenous ligands 
responsible for the activation of numerous transcription factors and signaling 
pathways (Houten, Watanabe, & Auwerx, 2006). The Farnesoid X Receptor (FXR) is 
known as the bile acid nuclear receptor as bile acids, more potently CDCA, serve as 
the physiological ligand and activator (Lefebvre, Cariou, Lien, Kuipers, & Staels, 
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2009).  FXR activation ultimately serves a protective role in the maintenance of low 
bile acid concentrations to support homeostasis by triggering transcription of target 
genes involved in bile acid metabolism (Eloranta & Kullak-Ublick, 2008).  When 
there is an over-production of bile acids in the liver, the bile acids bind to and activate 
FXR (Hageman, Herrema, Groen, & Kuipers, 2010).  FXR will then activate the 
transcription of the small heterodimer partner (SHP), which in turn binds to and 
inhibits the transactivation of the Liver Homolog-1 receptor (LHR-1).  This results in 
a negative feedback regulation of cholesterol 7-alpha hydroxylase (CYP7A1) 
expression, the rate limiting step in bile acid synthesis (Chiang, 2009). A down-
regulation of CYP7A1 results in a decrease in the production of bile acids and this 
allows circulating concentrations to stabilize to physiological levels (Lefebvre et al., 
2009).  In the intestines, when FXR is activated due to access bile acids, fibroblast 
growth factor-19 (FGF19) expression on the enterocytes is up-regulated and a signal is 
sent from the intestines to CYP7A1 in the liver to decrease bile acid synthesis for the 
regulation of bile acid concentrations (Chiang, 2009). As a ligand of FXR, CDCA also 
serves to control the efflux of bile acid from the liver through the activation of BSEP 
in an effort to maintain physiologically normal liver function in the absence of high 
bile acid levels (Y. Chen et al., 2013).   
When cholesterol levels are high, the liver x receptor (LXR) is activated (Zhao 
& Dahlman-Wright, 2010).  Oxysterol, an oxidized metabolite of cholesterol, acts as 
an endogenous ligand for LXR.  LXR is activated in response to an accumulation of 
cholesterol, and this leads to the induction of genes responsible for the maintenance of 
cellular cholesterol levels in both the liver and intestines (Faulds, Zhao, & Dahlman-
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Wright, 2010).  Activation of LXR also results in an increase of CYP7A1 expression 
in an effort to produce sufficient bile acid which aids in the emulsification and 
absorption of the excess cholesterol (Ory, 2004). Therefore, activation of LXR 
signaling has implications on overall cholesterol homeostasis via regulation of bile 
acid synthesis.   
Peroxisome proliferator-activated receptors (PPAR’s) are a group of 
transcription factors that play a role in the regulation of lipid metabolism (Ory, 2004; 
Pineda Torra, 2002).  PPAR’s function as a group of three receptor isoforms, PPARα, 
PPARβ, and PPARϒ (Ory, 2004).  Specifically, PPARα is responsible for the 
regulation of fatty acid oxidation and lipid and glucose metabolism (Ory, 2004).  
PPARβ is responsible for increased insulin sensitivity, and increased energy 
expenditure while PPARϒ plays a part in the management of insulin resistance (Ory, 
2004). Taken together, the activation of PPAR has implications for bile acid synthesis 
and bile composition, as well as disorders such as hyperlipidemia and diabetes 
(Yoshikawa et al., 2003).  
These nuclear receptors, and many more, serve as examples of how bile acid 
concentrations directly and indirectly affect the overall synthesis of various pathways, 
and paint the picture of a very intricate system taking place to ensure homeostasis. 
Further understanding of the complex role and regulation of these nuclear receptors 
with respect to bile acid synthesis and AKR1D1 and CYP8B1 expression under 
physiological bile acid conditions will further uncover their role and response in 
diseased conditions. 
Disease and Bile Acid: 
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The liver plays a role in both metabolism and detoxification. Any deviation 
from normal physiological function may result in any number of pathological 
outcomes.  This holds true for bile acid synthesis as well.  A deregulation of bile acid 
synthesis, bile acid composition and bile acid pool size may result in the exacerbation 
of metabolic disorders, gallstone formation, cholestasis, cirrhosis, and even cancer (Y. 
Chen et al., 2013; Eloranta & Kullak-Ublick, 2008; Hofmann, 2014; Jansen, 2007; 
Martinez-Augustin, 2008). Type-2 Diabetes (T2D) is a very common metabolic 
disorder characterized by hyperglycemia, insulin resistance and insulin deficiency. It 
has been shown that under physiologically normal conditions insulin inhibits CYP7A1 
expression, while glucagon increases it, and this regulates bile acid synthesis (Li, 
Chanda, Zhang, Choi, & Chiang, 2010). Elevated cholesterol levels can exacerbate 
T2D symptoms as well (Li et al., 2012; Prawitt, Caron, & Staels, 2011); however the 
mechanism is poorly understood. As a result of a deregulation of glucose homeostasis 
associated with T2D, elevated glucagon and glucose levels due to fasting fail to 
decline or be suppressed after a meal has been ingested (Nguyen & Bouscarel, 2008). 
This may be a mechanism by which the liver produces more bile acid in order to 
regulate glucose and lipid homeostasis after ingestion of a meal. Therefore, bile acid 
synthesis increases due to insulin deficiency and resistance, and indicates that 
metabolic disorders such as diabetes affect the rate of bile acid synthesis (Prawitt et 
al., 2011). Studies have shown that the bile acid pool size and composition are 
significantly altered in patients with uncontrolled T2D (Li et al., 2012).  More 
significantly, it has been established that in patients that present with uncontrolled 
T2D, concentrations of the individual bile acid CDCA were significantly lower in the 
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bile acid pool with no indication of change in CA concentrations (Brufau et al., 2010; 
Prawitt et al., 2011). Therefore, because AKR1D1 is responsible for the synthesis of 
CDCA, gaining a better understanding as to the role of AKR1D1 in T2D models can 
identify a mechanism by which CDCA synthesis may be manipulated to regulate 
metabolic distress.  
Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer and 
a deregulation of bile acid synthesis and homeostasis has been linked to HCC 
formation (Y. Chen et al., 2013). This is due to the fact that, because of the potent 
surfactant capabilities of bile acids, an accumulation of bile acids at high 
concentrations is potentially toxic and can subject the liver to carcinogenic outcomes 
(Halilbasic, Claudel, & Trauner, 2013).  It has been established that high 
concentrations of the more hydrophobic bile acids, such as CDCA, is toxic to the 
hepatocytes and can effect overall liver function (Lefebvre et al., 2009).  This toxicity 
may result in liver inflammation and hepatocyte DNA damage that may promote the 
occurrence of carcinogenesis (Martinez-Augustin, 2008).  Bile acid accumulation may 
also lead to cholestasis, and this has been linked to HCC progression (Y. Chen et al., 
2013).  Regulation of the production and accumulation of highly toxic bile acids, such 
as CDCA, may be a mechanism by which the occurrence or progression of HCC can 
be controlled.  In order to effectively control the production and accumulation of 
CDCA through bile acid synthesis, AKR1D1 expression must be tightly regulated.  
Understanding the pathogenesis that results from the accumulation of bile acids, such 
as the highly hydrophobic and toxic CDCA, via AKR1D1, may provide insight into a 
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novel therapy for prevention or treatment of diseases such as HCC and diabetes, 
among others.   
Another disorder that is linked to uncontrolled bile acid concentrations is 
intrahepatic cholestasis of pregnancy (ICP).  ICP is a condition that can be seen in 
certain pregnant women in their third trimester of pregnancy (Glantz, Marschall, & 
Mattsson, 2004). Pregnant women with ICP symptomatically present jaundice-like 
conditions in the presence or absence of pruritus (Glantz et al., 2004).  ICP is 
characteristically associated with increased serum bile acid concentrations in 
combination with a dysregulation of individual bile acids in the CDCA to CA ratio 
(Egan et al., 2012).  In physiologically normal conditions, including normal healthy 
pregnancies, the ratio of CDCA to CA concentrations is essentially equal; however, in 
conditions of ICP, women present with serum bile acid concentrations that contain 4 
times more CA in conjunction with a decrease in CDCA production (Egan et al., 2012; 
Laatikainen, Lehtonen, & Hesso, 1978). Diagnosis is most commonly made through 
the measurement of serum bile acid levels and if ICP is left untreated, there will be 
stresses onto the mother, and fetus as well (Glantz et al., 2004).  Thus, uncontrolled 
bile acid levels can result in adverse and possibly fatal consequences to the fetus 
(Glantz et al., 2004).  While the mechanism by which ICP occurs is still not 
definitively understood, it has been documented that increased estrogen levels and 
changes in expression of BSEP may contribute to ICP (Song et al., 2014).  Uncovering 
the transcriptional changes in expression of the genes that are responsible for the 
production of primary bile acids, such as AKR1D1, in the presence of estrogen may 
provide a potentially important link between pregnancy and cholestasis.   
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CYP8B1:  
 Sterol 12α-hydroxylase, CYP8B1, is cytochrome P450 enzyme responsible for 
the synthesis of the more hydrophilic bile acid, cholic acid (CA) (Ishida, Gotoh, 
Yamashita, Yoshida, & Noshiro, 1999).  To date, there has been much attention given 
to CYP8B1 linking its expression to the regulation of the CDCA to CA ratio within 
the bile acid pool (M. Zhang & Chiang, 2001). The foundations of these claims have 
been the targets of controversy, as the mechanism behind CYP8B1’s control of the 
bile acid ratio remains unclear.  There have been further reports which suggested a 
decreased trend in CYP8B1 expression with either CDCA or CA treatment of 
hepatocytes (Liu et al., 2014) while others have claimed that hydrophobic bile acids, 
and not hydrophilic bile acids, regulate the expression of CYP8B1 (M. Zhang & 
Chiang, 2001).  Changes in the expression of CYP8B1 have been documented in cases 
of diabetes with claims that CYP8B1 expression is increased in the absence of insulin 
(Ishida et al., 1999). 
 
AKR1D1:  
 Aldo-keto reductase 1D1, AKR1D1, is a 5β-reductase enzyme responsible for 
the synthesis of the hydrophobic primary bile acid, chenodeoxycholic acid, CDCA.  
The 5β-reductase, NADPH-dependent, activity of AKR1D1 incorporates a 90° bend in 
the structure of the enzyme and this is believed to add necessary solubility 
characteristics to subsequently produced bile acids (M. Chen & Penning, 2014).   
AKR1D1 is involved in the metabolism of several steroid hormones and also 
in the regulation of several hormone dependent processes.  In fact, AKR1D1 
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expression has been linked to regulating time of parturition (Sheehan, Rice, Moses, & 
Brennecke, 2005).  It has also been documented that, during pregnancy, increased 
expression of AKR1D1 serves to suppress contractions and thereby prevents pre-term 
birth (Pařízek, Koucký, & Dušková, 2014).  
There are many mutations associated with AKR1D1 expression and an inborn 
mutation of AKR1D1 can manifest itself into several liver-related abnormalities 
(Chaudhry et al., 2013; Drury, Mindnich, & Penning, 2010). For example, there is the 
potential for cholestasis as a result of alteration in the bile acid synthesis pathway and 
while treatment with primary bile acids tends to alleviate the condition, children born 
with an AKR1D1 deficiency that go untreated do not survive (Drury et al., 2010).   
AKR1D1 is the only enzyme in humans that is capable of catalyzing a 5β-
reduction in bile acids and steroids (M. Chen & Penning, 2014).  AKR1D1 expression 
is also necessary for bile acid synthesis.  While CYP7A1 is the rate-determining 
enzyme for total bile acid synthesis, little attention has been given to the enzymes that 
are responsible for the production of the individual primary bile acids.  Following 
CYP7A1, AKR1D1 or CYP8B1 are next synthesized for the production of either 
CDCA or CA, respectively.  While CYP8B1 has been identified as the enzyme that 
dictates the production of CDCA or CA and therefore influences the bile acid pool 
ratio, AKR1D1 expression should not go unnoticed.  This is due to the fact that 
AKR1D1 is not only responsible for the production of the primary bile acid CDCA, 
but also for the synthesis of CA.  After conversion of CYP7A1 to CYP8B1, another 
subsequent synthesis of CYP8B1 to AKR1D1 results in a 5β-reduction that is 
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necessary for CA synthesis.  It is for this reason that AKR1D1 should be considered a 
more potent player in bile acid synthesis.   
 
Conclusion:  
Due to CDCA’s highly toxic hydrophobic nature, controlling its production via 
AKR1D1 regulation is fundamentally important. Understanding the regulation of 
AKR1D1 in bile acid synthesis will ultimately unveil a novel approach to regulate 
CDCA production and the overall composition of the bile acid pool. The investigation 
into AKR1D1’s regulation can serve to provide drug therapies for such metabolic 
disorders as hyperlipidemia and diabetes, as well as treatment for disorders such as 
ICP, cardiovascular disease and liver cancer by regulating the production of the 
hydrophobic bile acid, CDCA.  
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CHAPTER 2 
COORDINATED REGULATION OF ALDO-KETO REDUCTASE 1D1 BY 
CHENODEOXYCHOLIC ACID AND CHOLIC ACID 
 
1. INTRODUCTION  
 Recently, it has been discovered that the role of bile acids is not only to serve 
as biological detergents, emulsifiers and the major route for cholesterol elimination, 
but to also to serve as intricate signaling hormones responsible for the regulation of 
numerous metabolic and regulatory processes such as cholesterol, lipid, energy, and 
glucose metabolism (Perez, 2009). Accordingly, impaired bile acid synthesis and 
signaling can lead to the occurrence, or exacerbation, of metabolic disorders such as 
obesity, diabetes, cholestasis, liver injury or cancer (Hofmann, 2014; Li & Chiang, 
2014; Perez, 2009).  
 One trend that is observed for many bile acid related cardiovascular and 
metabolic disorders is an imbalance in the bile acid pool size and composition 
(Chiang, 2009). Deregulation of CDCA and CA levels is reported to be associated 
with various disease conditions including intrahepatic cholestasis, diabetes and 
hepatocellular carcinoma (HCC). AKR1D1 and CYP8B1 are the two key enzymes for 
CDCA and CA synthesis, respectively. Due to their detergent-like properties, 
excessive bile acid accumulation can be toxic and therefore the size of the pool is 
tightly regulated (Chiang, 2009). On the other hand, bile acid can either be 
hydrophobic and more toxic in nature, such as CDCA or hydrophilic such as CA 
(Russell, 2003).  The composition of individual bile acids, or the ratio of CDCA to CA 
in the bile acid pool will greatly affect various physiological processes, such as the 
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rates of absorption and excretion of cholesterol and lipids(Russell, 2003).  CDCA 
more commonly inhibits cholesterol absorption while CA promotes cholesterol 
absorption (Russell, 2003).  For this reason, deregulation of the ratio or alteration of 
the bile acid pool composition may also lead to pathological consequences and 
influence disease conditions (Lefebvre et al., 2009).  Currently, it remains largely 
unknown how AKR1D1 and CYP8B1 are regulated to maintain homeostatic CDCA 
and CA levels. Furthermore, little is understood with regard to the underlying 
mechanisms that lead to bile acid pool alterations, which, in turn, give rise to 
physiological homeostasis or pathological circumstances.  
 Bile acids circulate between the liver and intestines via the tightly 
synchronized enterohepatic circulation.  Bile acids also function as signaling 
molecules, and not only control their own synthesis and regulation but also the gene 
expression of important nuclear receptors that are involved in various signaling 
pathways (Handschin & Meyer, 2005; Houten et al., 2006; Zwicker & Agellon, 2013). 
Many nuclear receptors and signaling pathways are also involved in the regulation of 
bile acid production through the rate limiting step of bile acid synthesis, cholesterol 
7a-hyroxylase, CYP7A1 (Russell, 2003).  The Farnesoid X Receptor (FXR) is also 
known as the bile acid receptor due to the fact that bile acids, mainly CDCA, serve as 
endogenous ligand (Chiang, 2009; Eloranta & Kullak-Ublick, 2008; Hageman et al., 
2010; Russell, 2003).  As bile acid levels increase FXR signaling results in not only a 
decrease of CYP7A1 expression and an increase in expression of essential transporter 
proteins necessary for bile acid movement (Chiang, 2009; Eloranta & Kullak-Ublick, 
2008; Lefebvre et al., 2009).   
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 Liver x receptor (LXR) is involved in cholesterol and lipid homeostasis (Ory, 
2004; Zhao & Dahlman-Wright, 2010). Oxysterols activate LXR in response to an 
accumulation of cholesterol, and this results in an increase of bile acid synthesis via 
CYP7A in order to produce sufficient bile acid to aid in the emulsification and 
absorption of excess cholesterol (Faulds et al., 2010; Ory, 2004; Zhao & Dahlman-
Wright, 2010). Peroxisome proliferator-activated receptors (PPAR’s) are another 
group of transcription factors that play a role in the regulation of lipid metabolism 
(Ory, 2004; Pineda Torra, 2002). PPAR agonists include fatty acids and fibrates which 
have implications on bile acid synthesis and bile composition, and also for disorders 
such as hyperlipidemia and diabetes (Mansour, 2014; Ory, 2004; Yoshikawa et al., 
2003). Research to understand how the activation of LXR or PPAR has implications 
on bile acid synthesis and/or bile acid related disorders may reveal novel mechanisms 
through which to regulate individual bile acid production.  
 A deregulation in the CDCA to CA ratio can result in toxicity and the 
exacerbation of diabetic symptoms, hepatocyte damage, death, or inflammation 
leading to cirrhosis, and ultimately, the progression of liver cancer (Hageman et al., 
2010; Li et al., 2012; Nguyen & Bouscarel, 2008; Perez, 2009). While it is known that 
bile acids regulate their own total synthesis by repression of CYP7A1 expression, little 
research has been done to investigate the regulation of individual bile acids (Russell, 
2003).  It is understood that AKR1D1 is responsible for the production of CDCA, and 
CYP8B1 is responsible for the production of CA, however regulation of their 
individual synthesis remains unclear.  Furthermore, little is known with regard to their 
involvement in the regulation and maintenance of the CDCA to CA bile acid ratio. 
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Due to CDCA’s highly toxic hydrophobic nature, physiological control of the 
production of CDCA, via AKR1D1 regulation, may logically be more fundamentally 
important for bile acid homeostasis and healthy liver function. It is the critical 
requirement of the liver to maintain homeostatic bile acid concentrations through the 
control of bile acid concentrations, therefore we hypothesize that regulation of 
AKR1D1, and not CYP8B1 is essential for healthy liver function.   
 At present, the regulation of AKR1D1 expression is not clearly understood.  
Thus, research to elucidate the mechanism by which AKR1D1 regulates the 
production of bile acid can uncover potentially innovative approaches for the 
modulation of the ratio of CDCA to CA in order to maintain physiologically normal 
concentrations.  Such coordinated regulation of bile acid will also be beneficial for the 
optimization of expression of bile acid associated target genes. Moreover, 
advancement in our knowledge on the overall regulation of bile acid synthesis, which 
leads to a balanced pool of hydrophobic and hydrophilic bile acids, may reveal novel 
mechanistic signaling pathways through which bile acid production and pool 
composition may be managed.  In the present study,  we examine the expression of 
AKR1D1 and CYP8B1 under physiologically normal bile acid concentrations and 
assess their regulation under activation of key cholesterol and lipid metabolism 
regulating pathways.   
2. MATERIALS AND METHODS 
2.1 Chemicals and Reagents:  
 Chenodeoxycholic acid (CDCA) and cholic acid (CA) were purchased from 
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Sigma-Aldrich.  PPAR agonist GW7647 and LXR agonist GW3965 were obtained 
from Tocris Biosciences.  Cell culture reagents Dulbecco’s modified Eagle’s medium 
(DMEM), and fetal bovine serum (FBS) as well as Taqman master-mix and RT-PCR 
probes were purchased from Life Technologies.  RNA Bee for RNA isolation, 
dimethyl sulfoxide (DMSO), and propanediol were obtained from Fisher Scientific.  
Primary and secondary antibodies for western blotting were purchased from 
SantaCruz Biotechnologies.  All western blotting gels, buffers, and markers were 
purchased through BioRad Laboratories.  Complementary DNA synthesis kit was 
purchased through Promega.  Protease inhibitor, Halt, and BSA protein quantification 
reagent were purchased from ThermoScientific.  
2.2 Treatment of HepG2 Cells  
HepG2 cells were seeded in 12-well plates at a cell density of 4.0 x 105 in 1.0 
mL DMEM supplemented with 10% (v/v) FBS, 1% (v/v) penicillin/streptomycin and 
1% (v/v) NEAA and cultured in a 5% CO2 incubator overnight at 37°C before 
treatment. After overnight incubation, cells were treated with 25uM CDCA or 25uM 
CA prepared in DMSO or a DMSO control treatment for 30 hours in 1 ml DMEM 
supplemented with 1% FBS, 1% antibiotics and 1% NEAA. All treatments were at 
0.1% of total volume medium. HepG2 cells were also seeded as described above and 
treated with LXR synthetic agonist GW3965 (1uM) or PPAR synthetic agonist 
GW7647 (25uM) prepared in DMSO or a DMSO negative control 30 hours in 1mL 
DMEM containing 1% FBS, 1% penicillin/streptomycin and 1% NEAA for a total 
concentration of 0.1%.   
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2.3 HepG2 RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction 
(RT-PCR) Analysis 
Thirty hours after treatment of HepG2 cells, cells were washed twice with 1X 
PBS and homogenized by pipetting with 0.25mL RNA-Bee reagent.  Homogenates 
were then transferred to 1.5mL microcentrifuge tube.  100uL chloroform was added to 
each tube and shaken vigorously for 30 seconds. The samples were then incubated on 
ice for 5 minutes and then centrifuged at 12,000 G’s for 15 minutes.  The supernatant 
was then transferred to a clean microcentrifuge tube and 0.5 mL propanediol was 
added.  The samples were then incubated at room temperature for 5 minutes after 
which they were spun at 12,000 G’s for 10 minutes.  The supernatant was discarded 
and the remaining pellet was washed with 70% ethanol in DEPC treated water and 
spun at 7,500 G’s for 5 minutes.  The supernatant was then discarded and the pellet 
was air dried for 10 minutes before being reconstituted in 30 uL DEPC water.  RNA 
was quantified by nano-drop and normalized to 2ug for reverse transcription into 
complementary DNA (cDNA) (Promega).  Applied Biosystems 7500 System 
Sequence Detection Software was used for Taqman RT-PCR data analysis. Using 
relative quantification (RQ), transcript levels of AKR1D1, CYP8B1 and CYP7A1 
were normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH).   
 
2.4 HepG2 Western Blotting  
Cells were washed in 1X PBS and homogenized in radioimmunoprecipitation 
assay (RIPA) buffer with 1% (v/v) protease inhibitors Halt and 1% (v/v) 
phenylmethanesulfonylfluoride (PMSF). The total cell lysate was homogenized by 
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vigorous pipetting and collected into a 1.5 mL micro-centrifuge tube to be spun at 
10,000 RPM at 4°C for 10 minutes.  The supernatant was collected into a clean micro-
centrifuge tube and quantified using a standard BSA assay.  After quantification, 
samples were normalized to 10ug of HepG2 protein lysate.  A 1:1 dilution of protein 
to laemilli sample buffer containing 1% (v/v) beta-mercaptoethanol was incubated at 
95°C for 5 minutes, spun, and loaded into a 4-20% gradient SDS-PAGE gel for 1 hour 
at 120V. Proteins were transferred from the gel using a semi-dry transfer apparatus 
onto methanol-wetted PVDF membranes at 20V for 30mins.  For antibody detection, 
membranes were blocked for 3 hours in 5% (w/v) skim milk dissolved into a 1X tris-
buffered saline solution containing 0.05% Tween20 (1X TBST).  Membranes were 
then incubated overnight at 4°C in a 1:500 dilution of primary antibody in 10mL of 
5% skim milk dissolved into a 1X TBST.  Membranes were probed for AKR1D1, 
CYP8B1, CYP7A1 (SantaCruz) or against GAPDH (SigmaAldrich).  After overnight 
incubation membranes were washed 3 times in 1X TBST and incubated with a 
corresponding 1:2000 HRP-conjugated secondary antibody for 2 hours.   
Chemiluminescent signals produced by HRP enzymes were detected using enhanced 
chemiluminescent substrates (Biorad Clarity Western ECL Substrate) and imaged 
under a Carestream Gel Logic 2200 Pro camera for 8 minutes. Expression of protein 
was quantified and normalized against GAPDH expression.  Where possible the same 
blot was stripped and re-probed with different antibodies.   
 
2.5 Plasmid Construct 
 Human AKR1D1 promoter reporter was prepared by cloning a -5.0kb fragment 
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upstream of the transcription start site of human AKR1D1 into a PGL4.10-Luc vector 
(Promega).   A PCR amplification was preformed using Promega GoTaq Long PCR 
system.  The DNA fragment was PCR amplified using human genomic DNA as a 
template as well as primers with the following sequences with the Promega GoTaq 
Long PCR reaction assembly.  The thermal cycling parameters were set to a 2 minute 
initial denaturation at 94°C followed by 35 cycles of a 30 second denaturation at 94°C 
and 5 minutes of annealing and extension at 65°C.  The PCR was concluded with a 
final extension at 72°C for 10 minutes. The 5kb hAKR1D1 PCR fragment was 
digested at the NheI and XhoI (New England BioLabs) sites over night at 37 °C and 
ligated into the PGL 4.10 luciferase reporter vector overnight at 16°C.  The plasmid 
was then transformed using DHα5 High Efficiency competent cells (Invitrogen) onto 
ampicillin treated agar plates at 37°C for 16-18 hours.  Following incubation, colonies 
were picked and grown in an ampicillin/LB broth while shaking for 16-18 hours.  
DNA from cultures was purified using a Promega Mini-prep kit. Reporter construct 
was sequence-verified before use in the experiments.  Dr. Matthew Stoner provided 
expression plasmids for FXRα2.  Dr. Bingfang Yan at the University of Rhode Island 
provided expression plasmids for LXRα, LXRβ, PPARα, PPARβ, and PPARγ.   
2.6 Reporter Luciferase Assay 
 HepG2 cells were seeded in 24-well plates at a cell density of 2.5 x 105 in 0.5 
mL DMEM supplemented with 10% (v/v) FBS, 1% (v/v) penicillin/streptomycin and 
1% (v/v) NEAA and cultured in a 5% CO2 incubator at 37°C overnight before 
treatment. After overnight incubation, cells were treated transiently transfected with 
GenJet Version II reagent.  For all transfections, a standard concentration of 100ng/ul 
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hAKR1D1 promoter reporter was used.  Additionally, 10ng/ul null-Renilla luciferase 
plasmid was used as an internal control.  Nuclear receptor expression plasmids 
(FXRα2, PPARα, PPARβ, PPARγ, LXRα, LXRβ) were also transfected at 100ng/ul.  
Twenty-four hours after transfection, cell medium was replaced with corresponding 
agonist treatment.  Treatment with 25uM CDCA, 50uM CDCA, 25uM CA, 1uM 
GW4064, 1uM GW3965, 20uM GW7647 prepared in DMSO or a DMSO control 
treatment for 30 hours in 1 ml DMEM supplemented with 1% FBS, 1% antibiotics and 
1% NEAA. All treatments were at 0.1% of total volume medium.   Following 30 hours 
treatment, cells were washed once with phosphate-buffered saline and lysed with 
100ul of 1X passive lysis buffer (Promega) by rocking at room temperature for 15 
minutes.  Following cell lysis, 10ul of cell lysate was transferred into a white 96-well 
plate for measurement of luciferase activity.  A Dual-Luciferase Reporter assay 
system was used to which measures the reporter vector firefly luciferase activity and 
subsequently the renilla luminesce of the null internal control.  The luminescence 
signal of the reporter vector was normalized based on the null reading.   
2.6 CDCA and CA Treatment of CD-1 Mice 
Eighteen male and female CD-1 mice were bred in-house and randomly 
separated into 3 groups of 6 mice at 6-8 weeks of age.  The mice had free access to 
food and water and were on a 12-hour dark/light cycle.  The mice were treated with 
CDCA or CA (SigmaAldrich) dissolved in propanediol, as well as a propanediol 
negative control. Mice were injected in the intraperitoneal cavity (IP) with treatment 
chemicals at 5-mg/kg body weight every 12 hours for 3 days for a total of 6 injections.    
Twelve hours after the last injection livers were harvested and processed for mRNA 
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and protein determination. The Institutional Animal Care and Use Committee 
(IACUC) at the University of Rhode Island approved all animal studies.  
 
2.7 LXR and PPAR Synthetic Agonists Treatment of C57BL/6 Mice 
Eighteen C57BL/6 male and female mice were bred in house and randomly 
separated into 3 groups of 6 mice at 6-8 weeks of age.  The mice were treated with 
GW3965 or GW7647 (Tocris) dissolved in propanediol as well as a propanediol 
negative control.  The mice had free access to food and water and were on a 12-hour 
dark/light cycle.  Mice were injected in the intraperitoneal cavity (IP) with treatment 
chemicals at 10-mg/kg body weight every 12 hours for 3 days for a total of 6 
injections.  Twelve hours after the last injection livers were harvested and processed 
for mRNA and protein determination.   
 
2.8 Mouse Liver RNA Isolation and Quantitative Real-Time Polymerase Chain 
Reaction (RT-PCR) Analysis 
  100mg of mouse liver was homogenized in 1 mL RNA-Bee for RNA 
extraction.   300 uL chloroform was added to each tube, which was then shaken 
vigorously for 30 seconds. The samples were then incubated on ice for 5 minutes 
before being centrifuged at 12,000 G’s for 15 minutes.  The supernatant was then 
transferred to a clean microcentrifuge tube and 0.5 mL propanediol was added.  
Samples were incubated at room temperature for 5 minutes and then spun at 12,000 
G’s for 10 minutes.  The supernatant was discarded and the remaining pellet was 
washed with 70% ethanol in DEPC treated water and spun at 7,500 G’s for 5 minutes.  
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The supernatant was then discarded and the pellet was air dried for 10 minutes before 
being reconstituted in 30 uL DEPC water.  RNA was quantified by nano-drop and 
normalized to 2ug for reverse transcription into complementary DNA (cDNA) 
(Promega).  Applied Biosystems 7500 System Sequence Detection Software was used 
for Taqman RT-PCR data analysis. Applied Biosystems 7500 System Sequence 
Detection Software was used for Taqman RT-PCR data analysis. Using relative 
quantification (RQ), transcript levels of AKR1D1, CYP8B1 and CYP7A1 were 
normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH).   
 
2.9 Mouse Liver Tissue Western Blotting 
100mg of liver tissue was homogenized in 1 mL of Sucrose-Tris buffer 
containing 1% Halt.  The total homogenate was spun in a micro-ultra centrifuge at 
100,000g’s at 4C to separate the cytosolic fraction from the membrane fraction.  
Cytosolic fraction protein was collected and transferred to a clean 1.5 mL 
microcentrifuge tube.  The protein was quantified using a standard BSA assay.  After 
quantification, protein samples were normalized to 100ug of cytosolic protein. A 1:1 
dilution of protein to laemilli sample buffer containing 1% (v/v) betamercaptoethanol 
was incubated at 95°C for 5 minutes, spun, and loaded into a 4-20% gradient SDS-
PAGE gel for 1 hour at 120V. Proteins were transferred from the gel using a semi-dry 
transfer apparatus onto methanol-wetted PVDF membranes at 20V for 30mins.  For 
antibody detection, membranes were blocked for 3 hours in 5% (w/v) skim milk 
dissolved into a 1X tris-buffered saline solution containing 0.05% Tween20 (1X 
TBST).  Membranes were then incubated overnight in a 1:500 dilution of primary 
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antibody in 10mL of 5% skim milk dissolved into a 1X TBST.  Membranes were 
probed for AKR1D1, CYP8B1, CYP7A1 (SantaCruz) or against GAPDH 
(SigmaAldrich).  After overnight incubation membranes were washed 3 times in 1X 
TBST and incubated with a corresponding 1:2000 HRP-conjugated secondary 
antibody for 2 hours.   Chemiluminescent signals produced by HRP enzymes were 
detected using enhanced chemiluminescent substrates (Biorad Clarity Western ECL 
Substrate) and imaged under a Carestream Gel Logic 2200 Pro camera for 8 minute 
exposure. Expression of protein was quantified normalized against GAPDH 
expression.  Where possible the same blot was stripped and re-probed with different 
antibodies.   
 
2.10 Statistical Analysis 
A Student’s t-test was applied to pairwise comparison for normally distributed 
data.  A p = .05 or lower was considered statistically significant.   
 
3. RESULTS 
3.1 Altered AKR1D1 expression with CDCA or CA treatment HepG2 Cells.   
 It remains to be determined how individual bile acid synthesis can be 
regulated.  While it is well established that AKR1D1 is responsible for the production 
of CDCA, its regulation is not fully understood.  To examine the effects of individual 
bile acids at physiological concentrations on endogenous expression of vital bile acid 
synthesis enzymes in HepG2 cells, cells were treated with either 25uM CDCA, 25uM 
  24 
CA or a DMSO negative control for 30 hours followed by mRNA and protein 
expression evaluation.  As shown in Figure 1A, RT-PCR analysis indicated that 
human AKR1D1 mRNA expression was significantly decreased by nearly 65% in 
HepG2 cells treated with CDCA (p < .01) as compared to the negative control cells 
treated with DMSO. In HepG2 cells treated with CDCA, CYP8B1 mRNA expression 
was not significantly altered as compared to DMSO treated control cells.  It should be 
noted that CYP7A1 expression was also measured as a positive control.  Consistent 
with published reports, CYP7A1 expression significantly decreased when treated with 
CDCA (p < .05) (Fig. 1A). 
 Protein expression of AKR1D1 in the presence of CDCA treatment in HepG2 
cells was also evaluated. Consistent with mRNA data, AKR1D1 protein expression 
was also significantly decreased (p < .01) in HepG2 cells with CDCA treatment by 
nearly 15% when compared to controls (Fig. 1B).  Expression of CYP8B1 was not 
significantly altered with CDCA treatment, however, as expected, CYP7A1 
expression significantly decreased (p < .05).  Taken together, these results evidence 
that CDCA regulate AKR1D1, and not CYP8B1, expression in a negative feedback 
manner at physiological concentrations.   
 With conclusive results that indicate that CDCA regulates the expression of 
AKR1D1, we next investigated the effects of CA on the expression of AKR1D1, 
CYP8B1 and CYP7A1.  HepG2 cells were treated with 25uM CA or a DMSO control 
for mRNA and protein quantification. Surprisingly, HepG2 cells exhibited a nearly 
two-fold increase in AKR1D1 expression when treated with CA (p < .05) (Fig. 2A).  
Interestingly, no significant change was observed in CYP8B1 or CYP7A1 expression 
  25 
(Fig. 2A).  To confirm the resulted from the collected mRNA data, protein expression 
was analyzed in response to CA treatment.  Consistent with the mRNA results, 
AKR1D1 expression in HepG2 cells was increased by over two-fold in the presence of 
CA as compared to DMSO treated control cells (p < .05) (Fig 2B).  No changes were 
observed in CYP8B1 or CYP7A1 expression at the protein level in response to CA 
treatment (Fig 2B).   The data clearly states that CA regulates AKR1D1 expression in 
a feed-forward manner.    
3.2 Altered Akr1d1 expression with CDCA or CA treatment in mice.  
 The previous results indicated that individual bile acids alter AKR1D1 
expression in-vitro in HepG2 cells.  Therefore, CD-1 mice were next tested to confirm 
the effect of individual bile acids on the bile acid synthesis pathway in-vivo.  The CD-
1 mice were injected with physiological concentrations of CDCA or  CA IP (10mg/kg) 
and analyzed for endogenous Akr1d1, Cyp8b1 or Cyp7A1 expression. Liver tissue 
was harvested and mRNA and protein were isolated for RT-PCR and western blot 
analysis.  Consistent with the in-vitro results, mRNA expression levels of Akr1d1 
exhibited a significant decrease (p < .05) with CDCA treatment by nearly 72% (Fig. 
3A).  As anticipated, Cyp8b1 expression was unchanged in CD-1 mice in the presence 
of CDCA.  Likewise, similar to our in-vitro data, Cyp7a1 RNA expression 
significantly decreased in the presence of CDCA treatment (p < 0.05).   
 As shown in Figure 3B, protein analysis also determined that Akr1d1 
expression significantly decreased by over 4-fold in CDCA treated mice (p < .05).  No 
change was observed in CYP8B1 expression and while there was a decreasing trend in 
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CYP7A1 expression, the results are not significant.   Collectively, the mRNA and 
protein data confirm that the findings in-vivo were consistent with the findings in-vitro 
that CDCA regulates the expression of Akr1d1 in either a negative feedback manner.   
 Mice were also treated with CA to examine the changes in RNA and protein 
expression of Akr1d1, Cyp8b1 and Cyp7a1. Mice exhibited an increased (although not 
significant) trend of Akr1d1 expression with CA treatment at the mRNA level (Fig. 
4A).  No significant changes were observed in mRNA expression of Cyp8b1 or 
Cyp7a1 with CA treatment.  As seen in Figure 4B, Akr1d1 protein expression was 
significantly increased by nearly 30% in mice with CA treatment (p < .01).  No 
change was observed in Cyp8b1 or Cyp7a1 expression with CA treatment.   
Collectively, the results demonstrated that individual primary bile acids 
regulate Akr1d1 expression.  Both CDCA and CA coordinately regulated Akr1d1, but 
not Cyp8b1, in either a negative feedback or positive feed-forward manner, 
respectively, in mice, under physiological conditions.   
3.3 CDCA mediated repression and CA mediated induction of AKR1D1 promoter.  
 The compiled results indicate that AKR1D1 expression, and not CYP8B1, is 
regulated by CDCA and CA in-vitro and in-vivo.  Therefore, additional data was 
collected to examine the promoter activity of AKR1D1 in the presence of primary bile 
acids. To determine if AKR1D1 promoter activity was transcriptionally regulated by 
CDCA and CA, a human AKR1D1 promoter reporter, phAKR1D1 (-5.0 kb), was 
prepared and transiently transfected into HepG2 cells.  Cells were treated with primary 
bile acid and relative luciferase activity was measured.  Results confirmed that 
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AKR1D1 promoter activity was decreased in a dose-dependent manner by CDCA (p < 
0.05) (Fig. 5A).  Furthermore, the human AKR1D1 promoter reporter exhibited 
significant increases in luciferase activity with treatment of CA (p < .05) (Fig. 5B).  
Taken together the data confirm that AKR1D1 expression is transcriptionally 
regulated by CDCA and CA in either a negative feedback, or positive feed-forward 
mechanism, respectively, in-vitro.   
3.4 FXR signaling is not involved in AKR1D1 expression.  
With confirmed results in-vitro and in-vivo demonstrating that at physiological 
concentrations CDCA and CA regulate AKR1D1, and not CYP8B1, expression, the 
effects of FXR activation on AKR1D1 expression were subsequently tested.  Since 
AKR1D1 is responsible for the synthesis of CDCA, and CDCA is a potent 
endogenous ligand for FXR, we investigated the relationship between FXR activation 
and AKR1D1 regulation.  The FXRα2 nuclear receptor was transfected into HepG2 
cells by transient transfection for 48 hours followed by harvesting of cells for RNA 
analysis to examine changes in endogenous AKR1D1 expression when FXRα2 is 
over-expressed in-vitro.  RT-PCR results presented no significant change in 
endogenous expression of AKR1D1 in control cells versus cells where FXRα2 was 
over-expressed (Fig. 6). These results indicate that over-expression of FXR has no 
implications on AKR1D1 expression. 
To further examine the effects of FXR activation on AKR1D1 expression, an 
in-vivo animal study was designed where mice were injected with the synthetic FXR 
agonist, GW4064 every 12 hours for 3 days at 10mg/kg.  The livers were subsequently 
harvested for RNA isolation.  RT-PCR results demonstrated that activation of the FXR 
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signaling pathway had no significant effect on endogenous AKR1D1 expression as 
compared to control mice (Fig. 7).  Consistent with our in-vitro results, the results 
confirm that AKR1D1 is not regulated by FXR. 
To ensure FXR expression was not indirectly associated with AKR1D1 
expression, an FXR knockout mouse model was used to examine endogenous 
AKR1D1 expression.  The livers of FXR knockout and wild-type control mice were 
analyzed for endogenous AKR1D1 RNA expression.  No changes were observed 
between wild-type and FXR knockout mice (Fig.8).  The data therefore demonstrated 
that FXR activation does not affect the expression of AKR1D1 and therefore FXR 
expression or activation does not regulate AKR1D1 expression 
3.5 Increase in PPAR activity decreases expression of AKR1D1 in-vitro and in-vivo. 
With conclusive data that FXR signaling is not involved in the regulation of 
AKR1D1, the effects of PPAR activation on AKR1D1 expression were subsequently 
tested in order to identify a novel activation or repression pathway. HepG2 treated 
with 25uM of the synthetic PPAR agonist, GW7647, were analyzed.  RNA results 
demonstrated that, as shown in Figure 9A, AKR1D1 expression in-vitro was 
significantly repressed nearly 10-fold when treated with the PPAR agonist (p <0.01). 
Similar to the RNA data, western-blotting results (Fig. 9B) demonstrated that protein 
expression of AKR1D1 also significantly decreased nearly 3-times with PPAR agonist 
treatment in HepG2 cells  (p < 0.05).  Taken together, the data suggests that activation 
of the PPAR signaling pathway decreases AKR1D1 expression in-vitro in HepG2 
cells.   
  29 
To confirm the results that were obtained in-vitro, which suggested that PPAR 
activation decreased AKR1D1 expression, the effect of AKR1D1 expression in-vivo in 
C57BL/6 mice was analyzed in response to treatment with 10mg/kg PPAR agonist 
GW7647.  As shown in Figure 10A, mouse Akr1d1 RNA expression was significantly 
decreased (p < 0.05) by more than 2 fold with treatment of GW7647.  Western blot 
results (Figure 10B) confirmed that protein expression of Akr1d1 was also 
significantly decreased nearly 2 fold with mice treated with GW7647 (p < 0.05).  In 
combination with the in-vitro data collected, the in-vivo the data confirms that 
activation of the PPAR signaling pathway consistently represses AKR1D1 expression.   
3.6 GW7647 mediated trans-repression of AKR1D1 promoter.  
 To further understand the mechanistic regulation of AKR1D1 by PPAR 
activation, transcriptional regulation of AKR1D1 was examined in-vitro.  The human 
AKR1D1 promoter reporter, phAKR1D1 (-5.0 kb) was co-transfected into HepG2 
cells with PPARα, PPARβ or PPARγ to identify isoform specific activation.  Cells 
were treated with 25uM GW7647 for 30 hours followed by measurement of relative 
luciferase signals.  The results indicate a decrease of AKR1D1 expression with all 
three PPAR isoforms. While a statistically significant decrease was only observed 
through the PPARγ isoform nuclear receptor (p < .001), all three isoforms displayed a 
decreased trend in AKR1D1 expression (Fig. 11).  Therefore, it can be stated that 
PPAR isoforms are binding to a previously un-identified PPAR response element 
within the 5kb human AKR1D1 promoter region and, upon activation, repress 
AKR1D1 expression. 
3.7 Possible involvement of PPARγ in AKR1D1 regulation. 
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 With the possible identification of a previously un-identified PPAR response 
element within the 5kb promoter region of human AKR1D1, repression of AKR1D1 
expression through PPAR in response to CDCA treatment was measured.  HepG2 
cells were transiently transfected with the phAKR1D1 (-5.0kb) promoter reporter and 
PPARα, PPARβ or PPARγ.  Relative luciferase activity was measured after 30 hours 
treatment with 25uM CDCA.  As shown in Figure 12, the results indicate an isoform 
specific transrepression of AKR1D1 by CDCA treatment, possibly through PPARγ (p 
< .05).  No change was observed in AKR1D1 expression with PPARα or PPARβ co-
transfection.  Therefore, the data suggests that PPARγ may be involved in the 
transcriptional repression of AKR1D1 through CDCA treatment.  
3.8 Activation of LXR signaling increases RNA and protein expression of AKR1D1 
in-vitro and in-vivo.  
With confirmed results that individual bile acids dictate the expression of 
AKR1D1, and not CYP8B1, the affects of LXR activation on AKR1D1 expression 
were next investigated in HepG2 cells.  HepG2 cells were treated with the synthetic 
LXR agonist GW3965 to investigate changes in AKR1D1 expression under LXR 
activation. RNA was isolated and analyzed for AKR1D1 expression by RT-PCR. The 
results shown in Figure 13A indicated that at the mRNA level, AKR1D1 expression 
was significantly (p < 0.05) increased by over 30% by activation of the LXR signaling 
pathway. Protein isolated from HepG2 cells treated with either a 0.1% DMSO control 
or 1uM GW3965 was analyzed by western blotting.  Protein results confirmed the 
increase, as seen at the RNA level, concluding that expression of AKR1D1 
significantly increased by over 30% with treatment of the LXR agonist (p < 0.05) in-
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vitro in HepG2 cells (Fig. 13B).  The data confirms that AKR1D1 expression is 
increased by LXR activation in-vitro.   
To confirm our in-vitro findings in an in-vivo model, mice were injected IP 
with the LXR synthetic agonist for 3 days, with injections every 12 hours.  Livers 
were harvested and analyzed for RNA and protein expression of AKR1D1 by RT-PCR 
and western blot, respectively.  In mice treated with the LXR synthetic agonist, no 
significant change was observed at the RNA level of Akr1d1 expression in 
comparison to vehicle treated mice (Fig. 14A). The results, however, were consistent 
with in-vitro protein expression and demonstrated that mouse Akr1d1 protein levels 
were significantly increased (p < 0.05) with LXR activation by nearly 50% (Fig. 14B).   
Taken together the data demonstrates that while activation of the LXR signaling 
pathway does not have implications on AKR1D1 expression at the transcript level, 
there are significant changes in protein expression.  This increase of AKR1D1 protein 
expression, which is not seen at the RNA level, may be due to an un-identified post-
translation modification.   
3.9 GW3965 mediated transactivation of AKR1D1 promoter.  
To further understand the mechanistic regulation of AKR1D1 by LXR 
activation, transcriptional regulation of AKR1D1 was examined in-vitro.  The human 
AKR1D1 promoter reporter, phAKR1D1 (-5.0 kb) was co-transfected into HepG2 
cells with LXRα or LXRβ to identify isoform specific activation.  Cells were treated 
with GW7647 for 30 hours and relative luciferase signals were measured. AKR1D1 
promoter reporter activity was significantly increased with co-transfection of LXRβ (p 
< .01), but not LXRα (Fig. 15).  The results indicate that an isoform-specific 
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transactivation of AKR1D1 expression exists, demonstrating that LXRβ binds to an 
LXR response element on the 5kb human AKR1D1 promoter region and through 
activation by an LXR agonist induces expression of AKR1D1.   
3.10 CDCA does not regulate AKR1D1 expression through LXR nuclear receptors. 
 With identification of a previously un-identified LXR response element in the 
5kb promoter region of the human AKR1D1 gene, the effects of LXR nuclear receptor 
activation through CDCA treatment was analyzed.  HepG2 cells were transiently 
transfected with phAKR1D1 (-5.0kb) and LXRα or LXRβ and treated for 30 hours 
with 25uM CDCA.  The results showed that CDCA does not regulated the expression 
of AKR1D1 through binding LXRα or LXRβ and no significant change or trend was 
observed (Fig. 16).   
4. DISCUSSION 
Due to their potential to cause toxicity to hepatocytes, individual bile acid 
concentrations within the bile acid pool must be tightly regulated to maintain 
physiological homeostasis and normal healthy liver function.  With respect to bile acid 
synthesis regulation, to date, much focus has been on CYP8B1 expression.  It has been 
argued that expression of CYP8B1 is the determining factor of individual primary bile 
acid synthesis and is therefore the influential enzyme in determining the ratio of 
CDCA to CA in the bile acid pool. Our data, however, demonstrates that it is in fact 
AKR1D1 expression, and not CYP8B1, that regulates the ratio of CDCA to CA in the 
bile acid pool. The data confirms that the primary bile acids, CDCA and CA, regulate 
the expression of AKR1D1 at both the transcriptional and translational levels.  This 
regulation of AKR1D1 is likely control bile acid synthesis in order to achieve 
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homeostasis within the circulating bile acid pool.  Altering the expression of AKR1D1 
may be one mechanism by which bile acid homeostasis is maintained in enterohepatic 
circulation.  In-vitro and in-vivo results reveal that CDCA and CA dictate the synthesis 
of their own production by regulating the expression of AKR1D1 in a negative 
feedback manner or positive feed forward manner, respectively, to ensure bile acid 
homeostasis and prevent toxic accumulation.  
Within the bile acid pool, when the content of the circulating bile acid ratio 
favors CDCA at high concentrations, CDCA signaling, in turn, results in a decreased 
expression of AKR1D1, not only to adjust the ratio of bile acid within the pool, but 
also to limit any potential pathological consequences associated with high CDCA 
concentrations.  On the other hand, as the content of the bile acid pool favors higher 
CA concentrations, CA signaling results in an increase of AKR1D1 expression, 
without effecting CYP8B1 expression, to accelerate production of CDCA.  CA is able 
to up-regulate expression of AKR1D1 without affecting CYP8B1 expression due to 
the fact that the 5β-reductase enzyme also exists prior to the formation of CA.  This 
feed-forward mechanism of AKR1D1 regulation via CA signaling will result in a 
more evenly composed bile acid pool composition by balancing the CDCA to CA 
ratio. Since the data clearly establishes that the liver is consistently attempting to 
achieve homeostatic bile acid levels by adjusting the expression level of AKR1D1 
under physiological conditions, we next investigated potential pathways by which 
AKR1D1 expression may be used to regulate bile acid synthesis.  
AKR1D1 is responsible for the synthesis of CDCA, and CDCA is the 
endogenous ligand for FXR, therefore we investigated the relationship between FXR 
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activation and AKR1D1 regulation. In-vitro data demonstrated that endogenous 
AKR1D1 expression was not altered in HepG2 cells as a result of FXR over-
expression. It was also observed that when mice were treated with the synthetic FXR 
agonist, AKR1D1 expression exhibited no change as compared to control mice. 
Likewise, in FXR knockout mice the endogenous expression of AKR1D1 displayed 
no change as compared to wild-type mice.  Therefore it was concluded that activation 
of the FXR signaling pathway was not involved in the regulation of AKR1D1 
expression. Consequently, greater focus was given to other signaling pathways that 
had implications on bile acid synthesis.   
Activation of PPAR is commonly associated with lipid metabolism and fatty 
acid oxidation (Hunt et al., 2000).  Fibrates, a common class of PPAR agonists, are 
synthetic ligands which, through the activation of the PPAR signaling pathway, treat 
hyperlipidemia to lower serum triglyceride levels and raise high-density lipoproteins 
(Grygiel-Górniak, 2014).  Fibrates are also known to decrease insulin resistance 
associated with metabolic disorders (Hunt et al., 2000).  Due to the fact that bile acids 
also serve to solubilize lipids to prevent hyperlipidemia, the relationship between bile 
acid synthesis and PPAR activation was subsequently investigated. In humans, it has 
been published that PPAR activation results in a decreased CDCA output but no 
change to CA production (Pineda Torra, 2002).  Published reports also indicate that 
expression of PPAR is increased in response to physiological concentrations of CDCA 
in HepG2 cells (Pineda Torra, 2002).  
Until now, it has only been confirmed that PPAR activation does in fact affect 
bile acid synthesis and bile composition, however the involvement of AKR1D1 has 
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not been established. With the data that has been collected, our research has 
consistently demonstrated that activation of PPAR results in a down-regulation of 
AKR1D1 expression at the translational and transcriptional level, in-vitro and in-vivo.   
Upon examination of isoform-specific activation of PPAR on the AKR1D1 promoter, 
all PPAR isoforms displayed a role in decreased expression of AKR1D1 with PPARγ 
more potently repressing expression. With activation of PPAR, AKR1D1 expression is 
decreased thereby explaining why PPAR activation results in a bile acid pool that is 
depleted of CDCA.   Taken together, the observed results indicate that, for the first 
time, a PPAR response element may exist on the AKR1D1 promoter region.   
In addition, it was proven that CDCA regulated expression of AKR1D1 
through PPARγ binding.  Activation of PPARγ has implications on glucose 
metabolism.  There are well established links between glucose homeostasis and bile 
acid homeostasis (Grygiel-Górniak, 2014).  It can be theorized that when bile acid 
levels are increased, bile acid and glucose homeostasis may be dysregualted.  In such 
instances, we hypothesize that CDCA may bind PPARγ and decrease AKR1D1 
expression. This will in-turn normalize and maintain both glucose and bile acid 
homeostasis.  While our data does not indicate a substantial decrease in AKR1D1 
expression through a CDCA and PPARγ complex as compared to CDCA alone, 
knowledge of the involvement of PPARγ may shed light on a means to control bile 
acid and glucose homeostasis by adjusting bile acid production under pathological 
conditions by activation of PPAR signaling through PPARγ.  
Activation of the LXR signaling pathway is primarily associated with high 
cholesterol levels, ultimately inducing transcription of genes within the bile acid 
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synthesis pathway that aid to alleviate the cholesterol overload.  Since bile acids are 
ultimately the primary means for cholesterol solubilization and removal, we next 
investigated a relationship between LXR activation and AKR1D1 expression.  Our 
results indicate that activation of LXR signaling consistently increases AKR1D1 
expression in-vitro at the transcriptional and translational levels.  It has been identified 
that CDCA and CA differ in their roles with regards to cholesterol absorption, with 
CDCA inhibiting absorption and CA promoting absorption. The up-regulation of 
AKR1D1 expression upon LXR activation may serve as a means to increase CDCA 
content in the bile thereby decreasing cholesterol absorption and resulting in an 
increase in cholesterol metabolism. The synthetic LXR agonist, GW3965 is a full 
agonist of both LXRα and LXRβ with more potent activation of LXRβ.  At the 
concentrations that the cells and mice were treated, however, activation of both 
isoforms was achieved.  While LXRα expression is highest in the liver, LXRβ is 
widely distributed within the body (Y. Zhang & Mangelsdorf, n.d.).  Our results 
indicate that despite activation of both LXRα and LXRβ, only the interaction between 
LXRβ and the LXRE results in a transactivation of AKR1D1 expression in HepG2 
cells. This data confirms the possible presence of a previously un-identified active 
LXR element (LXRE) on the promoter region of AKR1D1.  Follow-up testing on 
activation of LXR nuclear receptor via CDCA treatment determined that CDCA does 
not regulate AKR1D1 through LXR.   
Activation of LXR also significantly increased AKR1D1 expression in-vivo at 
the translational level.  The increase in AKR1D1 protein expression, which serves to 
increase CDCA production, may prove to be a mechanism by which LXR agonists aid 
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in the emulsification of cholesterol at high concentrations.  The data suggestions that 
since expression is unchanged at the mRNA level in-vivo that there must be a post-
translational modification that is resulting in an increase of AKR1D1 protein without 
change to AKR1D1 mRNA.  Currently the root of this post-translational modification 
has not yet been identified.    
 Understanding the regulation of bile acid synthesis can theoretically identify 
mechanisms that work to control the hydrophobicity of the circulating pool to ensure 
proper physiological liver function. Understanding the regulation of the enzymes 
involved in the bile acid synthesis pathway under physiological conditions may shed 
light on mechanisms by which homeostasis can also be achieved in conditions of 
disease.  Likewise, understanding the changes that occur to the individual bile acid 
composition within the CDCA to CA ratio during physiologically normal states and 
times of disease may provide insight into the regulation of the enzymes involved in 
bile acid synthesis. Our results demonstrate that not only bile acids, but LXR and 
PPAR signaling pathways as well, are involved in the regulation of AKR1D1 
expression all in an effort to control CDCA production and maintain proper liver 
function and homeostasis.   
 Our results demonstrated that CDCA and CA are key regulators of AKR1D1, 
but not CYP8B1, expression. It is confirmed that CDCA and CA coordinately regulate 
AKR1D1 expression in either a negative feedback or positive feed-forward manner, 
respectively.  Such coordinated down-regulation and up-regulation of AKR1D1 by 
primary bile acids represents a mechanism by which the liver maintains homeostatic 
bile acid levels under physiological condition. For the first time, our data suggests the 
  38 
presence of LXR and PPAR response elements on the human AKR1D1 promoter, 5kb 
upstream from the start of transcription. With confirmation that LXR and PPAR 
signaling pathways are involved in regulating AKR1D1 expression a possible means 
to regulate bile acid production may be established. It has been proven that there is a 
potential cross-talk between LXR and PPAR (Yoshikawa et al., 2003). Their 
involvement in regulating AKR1D1 may further explain their potential cross-talk.  In 
conclusion, CDCA and CA coordinately regulate AKR1D1, but not CYP8B1, 
expression, and activation of LXR and PPAR may be used to modulate bile acid 
production via AKR1D1 not only to maintain bile acid homeostasis, but also to 
ultimately aid in the treatment or alleviation of bile acid associated disorders. 
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CHAPTER 2 FIGURES 
Fig.%1%A%
p=#0.007#
DM
SO
25
uM
 C
DC
A
0.0
0.5
1.0
1.5
HepG2 Cell Treatment
Fo
ld
 C
ha
ng
e 
in
 R
N
A
 E
xp
re
ss
io
n
hAKR1D1
DM
SO
25
uM
 C
DC
A
0.0
0.5
1.0
1.5
HepG2 Cell Treatment
Fo
ld
 C
ha
ng
e 
in
 R
N
A
 E
xp
re
ss
io
n
hCYP8B1
DM
SO
25
uM
 C
DC
A
0.0
0.5
1.0
1.5
HepG2 Cell Treatment
Fo
ld
 C
ha
ng
e 
in
 R
N
A
 E
xp
re
ss
io
n
hCYP7A1
p=#0.007#
p=#0.05#
p=#0.726#
DM
SO
25
uM
 C
DC
A
DM
SO
25
uM
 C
DC
A
DM
SO
25
uM
 C
DC
A
0.0
0.5
1.0
1.5
HepG2 Cell Treatment
Fo
ld
 C
ha
ng
e 
in
 P
ro
te
in
 E
xp
re
ss
io
n
hAKR1D1
hCYP8B1
hCYP7A1
B" Fig."1"
p=#0.003#
p=#0.248#
p=#0.02#
 
  40 
 
Figure 1. The effects of CDCA treatment on RNA and protein expression of 
AKR1D1, CYP8B1 and CYP7A1 in HepG2 Cells.   
 
HepG2 cells were treated with 25uM CDCA in DMSO or a 0.1% DMSO vehicle 
control.  (A) At 30 hours incubation total RNA was isolated RT-PCR quantification.  
The abundance of mRNA encoding AKR1D1, CYP8B1 and CYP7A1 in HepG2 cells 
was measured and normalized against GAPDH. The data are presented as fold changes 
in relative expression of the mean of six replicates and a P< 0.05 was considered 
significant (Student-t test). (B) At 30 hours post-treatment with CDCA, 20ug of cell 
lysate was analyzed by western blot on a 4-20% gradient gel.  Expression of 
AKR1D1, CYP8B1 and CYP7A1 was quantified and normalized against GAPDH.  
The data are presented as fold changes in relative expression of the mean of at least 3 
replicates and a P< 0.05 was considered significant (Student’s t-test). 
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Figure 2. The effects of CA treatment on RNA and protein expression of 
AKR1D1, CYP8B1 and CYP7A1 in HepG2 Cells.   
 
HepG2 cells were treated with 25uM CA in DMSO or a 0.1% DMSO vehicle control.  
(A) At 30 hours incubation total RNA was isolated RT-PCR quantification.  The 
abundance of mRNA encoding AKR1D1, CYP8B1 and CYP7A1 in HepG2 cells was 
measured and normalized against GAPDH. The data are presented as fold changes in 
relative expression of the mean of six replicates and a P< 0.05 was considered 
significant (Student t-test). (B) At 30 hours post-treatment with CA, 20ug of cell 
lysate was analyzed by western blot on a 4-20% gradient gel.  Expression of 
AKR1D1, CYP8B1 and CYP7A1 was quantified and normalized against GAPDH.  
The data are presented as fold changes in relative expression of the mean of at least 4 
replicates and a P< 0.05 was considered significant (Student’s t-test). 
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Figure 3.   Effect of CDCA treatment on endogenous AKR1D1, CYP8B1 and 
CYP7A1 expression in-vivo. 
 
CD-1 mice were injected (6 per group) with propanediol vehicle or  10uM CDCA at 
5mg/kg IP.  Livers were harvested for RNA and protein analysis. (A) RNA was 
isolated from liver tissue.  Endogenous AKR1D1, CYP8B1 and CYP7A1 expressions 
were analyzed and normalized to GAPDH.   The data are presented as a fold change in 
relative expression of the mean of 6 mice as compared to the negative control and a p 
< 0.05 was considered significant (student t-test).  (B) Protein was isolated from liver 
tissue.  Endogenous AKR1D1, CYP8B1 and CYP7A1 expression were analyzed and 
normalized to GAPDH.   The data are presented as a fold change in relative expression 
of the mean of 6 mice as compared to the negative control and a p < 0.05 was 
considered significant (Student’s t-test).   
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Figure 4. Effect of CA treatment on endogenous AKR1D1, CYP8B1 and CYP7A1 
expression in-vivo. 
 
CD-1 mice were injected (6 per group) with propanediol vehicle or 10uM CA at 
5mg/kg IP.   Livers were harvested for RNA and protein analysis. (A) RNA was 
isolated from liver tissue.  Endogenous AKR1D1, CYP8B1 and CYP7A1 expression 
were analyzed and normalized to GAPDH.   The data are presented as a fold change in 
relative expression of the mean of 6 mice as compared to the negative control and a p 
< 0.05 was considered significant (student t-test).  (B) Protein was isolated from liver 
tissue.  Endogenous AKR1D1, CYP8B1 and CYP7A1 expression were analyzed and 
normalized to GAPDH.   The data are presented as a fold change in relative expression 
of the mean of 6 mice as compared to the negative control and a p < 0.05 was 
considered significant (Student’s t-test).   
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Figure 5. Alteration of human AKR1D1 promoter reporter expression with 
CDCA or CA treatment in HepG2 Cells.   
 
HepG2 cells were transiently transfected with the human AKR1D1 promoter reporter 
plasmid phAKR1D1 (-5.0 kb) and treated with primary bile acid for 30 hours.  
Luciferase activation was measured by a dual-luciferase reporter assay system.  (A) 
Luciferase activity of phAKR1D1 (-5.0 kb) in HepG2 cells with 25uM or 50uM 
CDCA treatment (B) Luciferase activity of phAKR1D1 (-5.0 kb) in HepG2 with 
25uM CA.  The data are presented as a fold change in relative expression of the mean 
of 3 replicates as compared to the negative control and a p < 0.05 was considered 
significant (Student’s t-test).   
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Figure 6.  Over-expression of FXRα2 in HepG2 Cells.   
 
HepG2 cells were transiently transfected with FXRα2 nuclear receptor.  Following 48 
hours transfection, RNA was isolated from cells and probed changes in endogenous 
AKR1D1 expression.  The data are presented as a fold change in relative expression of 
the mean of 3 replicates as compared to the negative pcDNA control and a p < 0.05 
was considered significant (Student’s t-test).   
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Figure 7.   Endogenous mAKR1D1 RNA expression with GW4064 treatment. 
 
Mice (6 per group) were treated with the FXR synthetic agonist GW4064 to examine 
changes in AKR1D1 expression.  The data are presented as a fold change in relative 
expression of the mean of 6 replicates as compared to the negative untreated control 
and a p < 0.05 was considered significant (Student’s t-test).   
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Figure 8. AKR1D1 expression in FXR -/- Mice 
 
RNA extracted from wild-type and FXR -/- mice (6 per group) was probed for 
endogenous mAKR1D1 expression and normalized to GAPDH.  The data are 
presented as a fold change in relative expression of the mean of 6 replicates as 
compared to the wild-type control and a p < 0.05 was considered significant (Student’s 
t-test).   
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Figure 9. AKR1D1 expression in HepG2 cells treated with the PPAR synthetic 
agonist GW7647. 
 
HepG2 cells were treated with 25uM GW7647 for 30 hours and RNA and protein 
were isolated.  (A) RNA was harvested for real-time PCR analysis for the detection of 
AKR1D1 expression and normalized against GAPDH. The data are presented as a fold 
change in relative expression of the mean of 3 replicates as compared to the negative 
control and a p < 0.05 was considered significant (Student t-test). B) HepG2 cell lysate 
protein was probed for endogenous AKR1D1 expression when treated with 25uM 
GW7647. Endogenous AKR1D1 expression was quantified in HepG2 cells and 
normalized against GAPDH.  The data presented are the fold change in relative 
expression of the mean of at least 3 replicates and a p < 0.05 was considered 
significant (Student’s t-test). 
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Figure 10. Endogenous AKR1D1 expression of mice treated with synthetic PPAR 
agonist, GW7647.  
 
Mice were injected every 12 hours for 3 days with 20uM GW7647.  Livers were 
harvested for RNA and protein analysis  (A) RNA was isolated from liver tissue for 
RT-PCR quantification.  AKR1D1 RNA expression as normalized against GAPDH.  
The data are presented as a fold change in relative expression of the mean of 6 
replicates as compared to the negative control and a p < 0.05 was considered 
significant (student-t test).  (B) Liver cytosolic protein was probed for endogenous 
AKR1D1 expression.  Endogenous AKR1D1 expression was quantified and 
normalized against GAPDH.  The data presented are the fold change in relative 
expression of the mean of 6 replicates and a p < 0.05 was considered significant 
(Student’s t-test). 
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Figure 11. Transrepression of hAKR1D1 promoter reporter by PPAR isoforms 
in response to GW7647 in HepG2 cells.    
 
HepG2 cells were transiently transfected with the human AKR1D1 promoter reporter 
phAKR1D1 (phAKR1D1 -5.0 kb) and co-transfected with PPARα, PPARβ or PPARγ 
and treated with either 25uM GW7647 or 0.1% DMSO control for 30 hours.  
Luciferase activation was measured by a dual-luciferase reporter assay system.  The 
data are presented as a fold change in relative expression of the mean of 3 replicates as 
compared to the negative control and a p < 0.05 was considered significant (Student’s 
t-test).   
 
 
 
 
  57 
Fig.%12%
PP
AR
a D
MS
O
PP
AR
a C
DC
A
PP
AR
b D
MS
O
PP
AR
b C
DC
A
PP
AR
g D
MS
O
PP
AR
g C
DC
A
0.0
0.5
1.0
1.5
HepG2 Cell Treatment
Fo
ld
 C
ha
ng
e 
in
 L
uc
ife
ra
se
 A
ct
iv
ity
5kb hAKR1D1 (-5.0 kb)p=#0.365# p=#0.143# p=#0.0432#
	  
Figure 12. Isoform dependent transrepression of human AKR1D1 by PPAR in-
vitro.   
PPARγ mediated transrepression of human AKR1D1 promoter reporter phAKR1D1 (-
5.0 kb) in the presence of 0.1% DMSO vehicle or 25uM CDCA.  Luciferase activation 
was measured by a dual-luciferase reporter assay system.  The data are presented as a 
fold change in relative expression of the mean of 3 replicates as compared to the 
negative control and a p < 0.05 was considered significant (Student’s t-test).   	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Figure 13.  AKR1D1 expression in HepG2 cells treated with LXR synthetic 
agonist GW3965.   
 
HepG2 cells were treated with 1uM GW3965 for 30 hours and RNA and protein were 
isolated.  (A) RNA was harvested for real-time PCR analysis for the detection of 
AKR1D1 expression and normalized against GAPDH. (B) HepG2 cell lysate protein 
was probed for endogenous AKR1D1 expression when treated with 1uM GW3965. 
Endogenous AKR1D1 expression was quantified in HepG2 cells and normalized 
against GAPDH.  The data presented are the fold change in relative expression of the 
mean of at-least 3 replicates and a p < 0.05 was considered significant (Student’s t-
test). 
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Figure 14.  AKR1D1 expression in mice treated with 15uM GW3965.   
Mice were injected every 12 hours for 3 days with 15uM GW3965 or a propanediol 
vehicle.  Livers were harvested for RNA and protein analysis  (A) RNA was isolated 
from liver tissue for RT-PCR quantification.  AKR1D1 RNA expression as 
normalized against GAPDH.  The data are presented as a fold change in relative 
expression of the mean of 6 replicates as compared to the negative control and a p < 
0.05 was considered significant (student t-test).  (B) Liver cytosolic protein was 
probed for endogenous AKR1D1 expression.  Endogenous AKR1D1 expression was 
quantified and normalized against GAPDH.  The data presented are the fold change in 
relative expression of the mean of 6 replicates and a p < 0.05 was considered 
significant (Student’s t-test). 
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Figure 15. Isoform dependent transactivation of human AKR1D1 by LXR in-
vitro.    
 
HepG2 cells were transiently transfected with a human AKR1D1 promoter reporter 
phAKR1D1 phAKR1D1 (-5.0 kb) with either LXRa or LXRb and treated with 1uM 
GW3965 or 0.1% DMSO vehicle for 30 hours.  Luciferase activation was measured by 
a dual-luciferase reporter assay system.  The data are presented as a fold change in 
relative expression of the mean of 3 replicates as compared to the negative control and 
a p < 0.05 was considered significant (Student’s t-test).   
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Figure 16. hAKR1D1 promoter reporter is not activated by LXRb in response to 
CDCA in HepG2 cells.    
 
HepG2 cells were transiently transfected with the human AKR1D1 promoter reporter 
phAKR1D1 (-5.0 kb) with either LXRa or LXRb and treated with 25uM CDCA or 
0.1% DMSO vehicle for 30 hours.  Luciferase activation was measured by a dual-
luciferase reporter assay system.  The data are presented as a fold change in relative 
expression of the mean of 3 replicates as compared to the negative control and a p < 
0.05 was considered significant (Student’s t-test).   
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CHAPTER 3 
 
THE ROLE OF ALDO-KETO REDUCTASE 1D1 IN TYPE II DIABETES AND 
HEPATOCELLULAR CARCINOMA 
1. Introduction 
Bile acids possess the distinguishing characteristic of being detergents and 
surfactants and therefore their concentrations must be tightly regulated. Not only can 
increases in total bile acid levels result in pathological consequences, but increases in 
the concentrations of individual bile acids, which result in changes to the CDCA to 
CA ratio, can also affect normal healthy liver function.  Pathological conditions 
associated with dysregulation of bile acid concentrations range from cholestasis and 
cirrhosis to diabetes and hepatocellular carcinoma (HCC).   
 Type-2 diabetes (T2D) is a metabolic disorder characterized by insulin 
deficiency and resistance resulting in hyperglycemia as a result of genetic or 
environmental factors.  T2D generally presents later in life and its onset is associated 
with obesity and hyperlipidemia.  The maintenance of glucose and cholesterol levels 
in T2D patients is critical to avoid cardiovascular complications.  Due to the increased 
incidence of hyperlipidemia in conditions of altered glucose homeostasis, and known 
role of bile acid in lipid metabolism, a link between bile acid metabolism and glucose 
homeostasis has been established There is evidence that bile acid metabolism is 
altered in conditions of T2D suggesting that insulin and glucose modulate bile acid 
synthesis.  There are further indications that medications intended to lower cholesterol 
levels can also be used to improve glycemic control.  Bile acid sequestrates are resins 
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that bind bile acid and prevent them from being reabsorbed from the gut through 
enterohepatic circulation (Hansen, Sonne, & Knop, 2014).  With less bile acid in 
circulation, bile acid synthesis is increased and therefore cholesterol turn over to bile 
acid is increased and subsequently plasma glucose is decreased. .  It is suggested that 
the link between bile acid and glucose homeostasis is through FXR activation 
indicating that glucose induces FXR expression and insulin inhibits (Duran-Sandoval 
et al., 2004).  It has been well established that the CDCA composition of the bile acid 
pool is lower in patients with diabetes (Nguyen & Bouscarel, 2008), however the 
mechanism by which this occurs is unclear. Understanding the role of bile acid 
synthesis in diabetic models may identify a mechanism by which CDCA production is 
being regulated.  While our previous data confirms that there is no correlation between 
FXR and AKR1D1 expression, there may be one between diabetes and AKR1D1.   
Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer.  It 
has been identified that high concentrations of CDCA are toxic to the hepatocytes and 
can have carcinogenic effects; therefore understanding the regulation of CDCA 
production may prove important for prevention or progression of HCC. Hepatocellular 
damage may occur as the result of infection, cirrhosis, obesity, diabetes or 
accumulation of bile acids (Qian & Fan, 2005). Hepatocellular damage is associated 
with the release of cytokines, chemokines and other molecules that amplify the 
pathological response to cell injury (Perez, 2009).  It has been established that bile 
acids contribute to the formation of HCC by numerous studies that have reported 
spontaneous tumor development with the loss of the bile acid receptor, FXR (Kim et 
al., 2007; Yang et al., 2007).  Not only is FXR function associated with HCC 
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formation, but decreased expression of BSEP has also been reported (Y. Chen et al., 
2013).  As bile acid concentrations exceed binding capacity of ligands necessary for 
excretion and regulation, toxicity and subsequent cell damage may occur with the 
possibility of HCC. It can therefore be suggested that at excessive concentrations bile 
acids may be considered carcinogenic (Jansen, 2007).  It should be noted that it is not 
only important to regulate total bile acid synthesis, but individual concentrations 
should also be regulated.  CDCA is considered more toxic than CA because of its 
characteristic increased hydrophobicity and low micellular concentration (Attili, 
Angelico, Cantafora, Alvaro, & Capocaccia, 1986).   The emulsifying properties 
associated with bile acids are increased with CDCA due to the 5b-reductase activity of 
AKR1D1 which incorporates a 90° bend in the bile acid structure, contributing to the 
detergent-like characteristic (Russell, 2003).   
With knowledge that high concentrations of toxic bile acids, such as CDCA, 
may result in severe pathological circumstances such as exacerbation of diabetic 
symptoms as well as the progression of HCC, we investigate the role of AKR1D1 
expression in diseased conditions.  Understanding the role AKR1D1 plays in the 
synthesis of CDCA under pathological situations may provide insight into 
mechanisms by which AKR1D1 can be regulated to alleviate or prevent various 
metabolic disorders and cancers.   
 
3. MATERIALS AND METHODS 
3.1 Chemicals and Reagents:  
 Taqman master-mix and RT-PCR probes were purchased from Life 
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Technologies.  RNA Bee for RNA isolation, and propanediol were obtained from 
Fisher Scientific.  Primary and secondary antibodies for western blotting were 
purchased from SantaCruz Biotechnologies.  All western blotting gels, buffers, and 
markers were purchased through BioRad Laboratories.  Complementary DNA 
synthesis kit was purchased through Promega.  Protease inhibitor, Halt, and BSA 
protein quantification reagent were purchased from ThermoScientific.  
3.2 Normal, Diabetic and HCC Human Liver Tissue 
 Human normal, HCC tumor and diabetic liver tissue were obtained from the 
University of Virginia, University of Pennsylvania and Ohio State University through 
the Cooperative Human Tissue Network.  The institutional review board at the 
University of Rhode Island approved the use of human tissues.   
3.3 Normal, diabetic and HCC Human Liver RNA Isolation and Quantitative Real-
Time Polymerase Chain Reaction (RT-PCR) Analysis 
100mg of human liver tissue was homogenized in 1 mL RNA-Bee for RNA 
extraction.   300 uL chloroform was added to each tube, which was then shaken 
vigorously for 30 seconds. The samples were then incubated on ice for 5 minutes 
before being centrifuged at 12,000 G’s for 15 minutes.  The supernatant was then 
transferred to a clean microcentrifuge tube and 0.5 mL propanediol was added.  
Samples were incubated at room temperature for 5 minutes and then spun at 12,000 
G’s for 10 minutes.  The supernatant was discarded and the remaining pellet was 
washed with 70% ethanol in DEPC treated water and spun at 7,500 G’s for 5 minutes.  
The supernatant was then discarded and the pellet was air dried for 10 minutes before 
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being reconstituted in 30 uL DEPC water.  RNA was quantified by nano-drop and 
normalized to 2ug for reverse transcription into complementary DNA (cDNA) 
(Promega).  Applied Biosystems 7500 System Sequence Detection Software was used 
for Taqman RT-PCR data analysis. Using relative quantification (RQ), transcript 
levels of AKR1D1 and CYP7A1 were normalized against glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH).   
3.4 Normal, diabetic and HCC Human Liver Tissue Western Blot 
100mg of liver tissue was homogenized in 1 mL of Sucrose-Tris buffer 
containing 1% Halt.  The total homogenate was spun in a micro-ultra centrifuge at 
100,000g’s at 4C to separate the cytosolic fraction from the membrane fraction.  
Cytosolic fraction protein was collected and transferred to a clean 1.5 mL 
microcentrifuge tube.  The protein was quantified using a standard BSA assay.  After 
quantification, protein samples were normalized to 100ug of cytosolic protein. A 1:1 
dilution of protein to laemilli sample buffer containing 1% (v/v) betamercaptoethanol 
was incubated at 95C for 5 minutes, spun, and loaded into a 4-20% gradient SDS-
PAGE gel for 1 hour at 120V. Proteins were transferred from the gel using a semi-dry 
transfer apparatus onto methanol-wetted PVDF membranes at 20V for 30mins.  For 
antibody detection, membranes were blocked for 3 hours in 5% (w/v) skim milk 
dissolved into a 1X tris-buffered saline solution containing 0.05% Tween20 (1X 
TBST).  Membranes were then incubated overnight in a 1:500 dilution of primary 
antibody in 10mL of 5% skim milk dissolved into a 1X TBST.  Membranes were 
probed for AKR1D1, CYP7A1 (SantaCruz) or against GAPDH (SigmaAldrich).  After 
overnight incubation membranes were washed 3 times in 1X TBST and incubated 
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with a corresponding 1:2000 HRP-conjugated secondary antibody for 2 hours.   
Chemiluminescent signals produced by HRP enzymes were detected using enhanced 
chemiluminescent substrates (Biorad Clarity Western ECL Substrate) and imaged 
under a Carestream Gel Logic 2200 Pro camera for 8 minutes. Expression of protein 
was quantified and normalized against GAPDH expression.  Where possible the same 
blot was stripped and re-probed with different antibodies.   
3.5 Immunohistochemistry of normal, diabetic and HCC liver tissue 
Normal, diabetic and HCC human liver tissue slides were purchased from 
AbCam.  Slides were incubated at 60C for 30mins to melt paraffin.  Slides were 
transferred into Xylene two times for 3 minutes.  Slides were rehydrated in Ethanol 
(100%, 95%, and 70%) for 3 minutes.  Endogenous peroxidase activity was quenched 
to assist in secondary antibody binding by incubating slides in 3% H2O2 for 30 
minutes.  Slides were washing in 1X PBS 3 times for 5 minutes.  Antigen retrieval was 
conducted to increase the affinity of the gene to the receptor in 10mM Citrate Buffer 
by microwaving slides at 90% power until boiling and continuing to incubate at room 
temperature for 30 minutes.  Slides were then rinsed with 1X PBS- 0.1% Tween 20 to 
permeablize cells to allow antibody binding.  Nonspecific binding was blocked by 
using 5% BSA in 1X TBS- 0.1% TX-100 for 2 hours on shaker at room temperature.  
Primary antibodies AKR1D1 were incubated at 1:500 in 5% BSA in 1X TBS- 0.1% 
TX-100 over night at 4C.  Sections were then washed three times for 30minutes in 1X 
TBS- 0.1% TX-100.  A fluorescent secondary antibody was used against the primary 
antibody.  AlexaFluor 594 Goat Anti-Rabbit (Invitrogen A11012) was used at a 
dilution of 1:500 against all three primary antibodies.  Secondary antibody was 
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incubated for 1.5 hours on a shaker at room temperature while covered.  Slides were 
then washed 3 times for 10 minutes in 1X TBS.  Sections were then mounted under a 
glass cover slip using Vectashield Mounting Medium with a DAPI nuclei counterstain 
(Vector H-1500).  Images were captured under a confocal microscope at a 
magnification of 40X (Zeiss AxioImager M2 Imaging System).   
3.6 Statistical Analysis 
A Student’s t-test was applied to pairwise comparison for normally distributed data.  P 
.05 or lower was considered statistically significant.   
4. RESULTS 
4.1 AKR1D1 expression is altered in conditions of diabetes.  
 Bile acid homeostasis is known to play a role in glucose homeostasis.  For this 
reason, in diabetic conditions, bile acid pools sizes are altered.  To examine the role of 
AKR1D1 expression in livers of patients with diabetes, human livers were 
homogenized and RNA and protein expression of endogenous AKR1D1 was 
quantified as compared to healthy normal human liver tissue.  The results in Figure 
18A demonstrate that expression of AKR1D1 RNA was significantly decreased in 
livers of patients with diabetes as compared to those of normal liver tissue at the 
transcript level (p < .001).  To determine if changes in RNA and protein expression 
were specific to AKR1D1 in diseased diabetic livers, the expression of CYP7A1 was 
also investigated. The data demonstrated that CYP7A1 expression was not changed at 
the RNA level in diabetic livers as compared to normal livers (Fig. 18B).   
Western blot analysis was conducted to determine the effect of AKR1D1 and 
CYP7A1 expression at the protein level (Fig. 19A).  Consistent with RNA results, 
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AKR1D1 protein expression was significantly decreased in the diseased diabetic livers 
as compared to normal livers (p < .0001) (Fig. 19B), however no change was observed 
in CYP7A1 protein expression.   
 To visually examine the localization and expression of the AKR1D1 protein in 
human tissue, immunohistochemistry was conducted.  Images were captured on slides 
containing either normal human liver tissue or diabetic human liver tissue sections and 
were probed with AKR1D1 antibody.  The results indicate that, as confirmed in the 
western blot data, AKR1D1 expression is decreased in diabetic human tissue as 
compared to the normal human tissue (Fig. 20).  
Collectively the data establishes that AKR1D1 expression, and not CYP7A1, is 
altered in diabetics livers as compared to normal healthy livers.  It is currently not 
clear if these results explain if in conditions of disease the liver adjusts AKR1D1 
expression in order to limit CDCA production to prevent additional toxicity to an 
already diseased liver or if the decrease in AKR1D1 expression is in fact part of the 
progression of the diseased liver.   
4.2 Altered AKR1D1 expression in HCC Livers.  
Dysregulation of bile acid synthesis, and subsequently related inflammation 
and toxicity are known risk factor correlated with the progression of HCC.  Due to the 
characteristic toxicity associated with high levels of CDCA, the role of AKR1D1 
expression in human HCC livers was examined.  Normal and HCC human livers were 
homogenized and analyzed for expression of AKR1D1 and CYP7A1.  RT-PCR 
analysis demonstrated that expression of AKR1D1 RNA was significantly decreased 
in human HCC livers as compared to normal livers (p < 0.001) (Fig. 21A).  At the 
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RNA level, there was no significant change in CYP7A1 expression in HCC liver 
tissue as compared to normal human liver tissue.   
 Correspondingly, when examining protein expression of AKR1D1 by western 
blot analysis (Fig. 22A), there was a significant decrease in HCC human liver tissue as 
compared to normal tissue (p < .001) (Fig. 22B).  Western blot data reveals at 
expression of CYP7A1 was unchanged in HCC human liver as compared to normal 
human liver. Immunohistochemistry imaging confirmed western blot results by 
demonstrating that AKR1D1 expression was decreased in human HCC liver tissue 
slides as compared to normal liver tissue (Fig. 23).  
In conclusion, the combined data confirms that in patients with HCC, 
expression of AKR1D1 is significantly downregulated.  The data suggests that the 
liver may alter AKR1D1 expression in diseased cancerous liver tissue as an adaptive 
mechanism to protect the hepatocytes and liver from further damage associated with 
the more toxic hydrophobic primary bile acid, CDCA.  Expression of CYP7A1 is 
unchanged indicating that changes in AKR1D1 expression are not specific to the bile 
acid synthesis pathway, but that AKR1D1 expression is being regulated through an 
alternate signaling pathway.     
5. DISCUSSION 
 Bile acids are essential, at physiological concentrations, to aid in the 
emulsification and absorption of cholesterol, dietary fats and lipids.  Due to their 
characteristic properties of being biological surfactants and detergents, increased bile 
acid concentrations may be toxic to the hepatocytes and liver and therefore must be 
tightly regulated to maintain proper physiological liver function.  Uncontrolled 
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concentrations of toxic bile acids have the ability to cause inflammation of 
hepatocytes leading to apoptosis and necrosis and ultimately liver damage and the 
possibility cancer.  Damage to the hepatocyte has the potential of activating a series of 
signaling pathways associated with inflammatory modulators, oxidative stress, cellular 
damage and death.  A dysregulation in the composition of the bile acid pool may 
manifest itself into a number of pathological consequences.  Among these are 
metabolic disorders such as diabetes, as well as cancerous outcomes such as 
hepatocellular carcinoma, HCC.  
 It has been established that bile acid homeostasis is essential for proper 
metabolic homeostasis and function (Nguyen & Bouscarel, 2008).  Published data 
states that activation of FXR signaling decreased plasma glucose concentrations and 
increased insulin sensitivity in fasting diabetic mice models (Li et al., 2012).  
Likewise, it is known that in diabetic patients there is an increase in the size of the bile 
acid pool. On a study conducted on diabetes induced rats, it was established that while 
insulin inhibits FXR, glucose induces FXR expression (Duran-Sandoval et al., 2004).  
Another link between bile acid synthesis and glucose homeostasis is seen through the 
use of bile acid sequestrants.  Bile acid sequestrants are resin molecules that bind bile 
acid and preventing them from partaking in enterohepatic circulation.  Bile acid 
sequestrants are traditionally used to treat hyperlipidemia.  The loss of bile acid within 
the bile acid pool promotes the synthesis of additional bile acids to aid in cholesterol 
solubilization.  Recently bile acid sequestrants have been seen to aid in glucose 
homeostasis as well (Hansen et al., 2014).  Patients taking bile acid sequestrants show 
an improvement in glycemic control (Staels & Fonseca, 2009).  Taken together, the 
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association between bile acid homeostasis and glucose homeostasis is clear however 
the mechanism is not yet defined.   
In our study we examined the expression of AKR1D1 in diabetic human liver 
tissue to attempt to fill in the gap between bile acid homeostasis and glucose 
homeostasis through alterations in bile acid synthesis.  Our results indicated that RNA 
and protein expression of AKR1D1 was significantly decreased in diabetic patients as 
opposed to normal healthy patients, with no change to CYP7A1 expression.  Since 
AKR1D1 is responsible for the synthesis of the more hydrophobic bile acid CDCA, 
our data presumes a possible link between CDCA synthesis and either the prevention 
or pathogenesis of adverse diabetic outcomes. Consistent with our findings of a 
decrease in AKR1D1 expression of diabetic patients, it has been documented that the 
bile acid pool of diabetes-induced mice shows a significant decrease in CDCA 
concentrations (Li et al., 2012). With the knowledge that glucose binds FXR and aids 
in decreasing plasma glucose concentration (Duran-Sandoval et al., 2004), and CDCA 
binds FXR and aids in decreasing bile acid synthesis, our data serves to prove that the 
liver down-regulates AKR1D1 expression in order to prevent competitive binding of 
FXR in conditions of metabolic disease.  Furthermore, if a down-regulation of 
AKR1D1 expression is associated with a preventative measure, we hypothesize that 
the liver is altering AKR1D1 expression in order to control further production of the 
more hepatotoxic CDCA to protect a liver that is already diseased due to diabetes-
associated indications. While a pathway for this method has not yet been established, 
this novel mechanism by which the liver is attempting to regain homeostasis in times 
of disease would explain the decrease in AKR1D1 expression.  This mechanism would 
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also confirm our belief that due to the toxic nature of CDCA, the liver is constantly 
attempting to maintain homeostasis by altering AKR1D1 expression.   
Hepatocellular carcinoma (HCC) is one of the most common types of liver 
cancer and its advancement is linked to complications with hepatitis infections, 
obesity, cirrhosis, and disorders in bile acid synthesis.   Excess bile acid accumulation 
has been linked to the progression of HCC.  Due to the fact that CDCA is considered 
the more toxic bile acid as a result of its increased hydrophobicity, we examined the 
expression of AKR1D1 in patients with HCC and compared them to healthy normal 
human liver.  Our results demonstrated that expression of AKR1D1 was severely 
diminished in HCC patients as compared with normal healthy livers.  The down-
regulation of AKR1D1 expression was documented at both the transcript and protein 
levels.  Taken together we believe that the expression of AKR1D1 is down-regulated 
in HCC patients in a hepato-protective manner.  Due to the toxicity associated with an 
accumulation of bile acids, especially CDCA, the liver may alter AKR1D1 expression 
as a means to protect hepatocytes from further CDCA production.  Our lab previously 
reported a decrease in BSEP expression in HCC liver tissue (Y. Chen et al., 2013).  A 
decrease in BSEP expression will result in bile acid that is sequestered within the liver 
and cannot be secreted out, exacerbating toxic conditions for the liver and hepatocytes 
and ultimately contributing to the pathogenesis of HCC.  This data supports our 
hypothesis that AKR1D1 is down-regulated to suppress further CDCA production in 
conditions of hepatocellular stress or toxicity.   
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In conclusion, our data proves that in conditions of metabolic distress and 
HCC, the AKR1D1 expression is altered to limit the production of CDCA to prevent 
further toxicity.   
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CHAPTER 3 FIGURES 
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Figure 17.  Endogenous AKR1D1 and CYP7A1 mRNA expression in normal and 
diabetic human liver tissue.  
 
 
RNA expression of (A) AKR1D1 and (B) CYP7A1 were measured in normal and 
diabetic human liver tissue.  The data are presented relative expression of the mean of 
20 replicates and a p < 0.05 was considered significant (Student’s t-test).   
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Figure 18.  Endogenous AKR1D1 and CYP7A1 protein expression in normal and 
diabetic human liver tissue.  
 
 
 (A) Protein levels of AKR1D1 and CYP7A1 in normal and diabetic human liver 
tissue were detected by western blot.  (B) Quantification of AKR1D1 and CYP7A1 
protein expression in normal and diabetic human liver tissue.  The data are presented 
relative expression of the mean of 8 replicates and a p < 0.05 was considered 
significant (Student’s t-test).   
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Figure 19.  Expression of AKR1D1 in normal and diabetic human liver tissue.  
 
Liver sections were subjected to immunohistofluorescent assays.   Images were 
captured under a confocal microscope at a magnification of 40x with both fluorescent 
and DIC settings.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  82 
A" Fig."20"
Normal HCC
0
5
10
15
20
25
Human Liver Tissue
R
el
at
iv
e 
A
K
R
1D
1 
R
N
A
 E
xp
re
ss
io
n
AKR1D1
p=#0.0003#
 
Fig.%20%
Normal HCC
0
2000
4000
6000
Human Liver Tissue
R
el
at
iv
e 
C
Y
P
7A
1 
R
N
A
 E
xp
re
ss
io
n
CYP7A1
B%
p=#0.279#
 
  83 
Figure 20.  Endogenous AKR1D1 and CYP7A1 mRNA expression in normal and 
HCC human liver tissue.  
 
 
RNA expression of (A) AKR1D1 and (B) CYP7A1 were measured in normal and 
HCC human liver tissue.  The data are presented relative expression of the mean of 20 
replicates and a p < 0.05 was considered significant (Student’s t-test).   
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Figure 21.  Endogenous AKR1D1 and CYP7A1 protein expression in normal and 
HCC human liver tissue.  
 
 
 (A) Protein levels of AKR1D1 and CYP7A1 in normal and HCC human liver tissue 
were detected by western blot.  (B) Quantification of AKR1D1 and CYP7A1 protein 
expression in normal and HCC human liver tissue.  The data are presented relative 
expression of the mean of 8 replicates and a p < 0.05 was considered significant 
(Student’s t-test).   
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Figure 22.  Expression of AKR1D1 in normal and HCC human liver tissue.  
 
Liver sections were subjected to immunohistofluorescent assays.   Images were 
captured under a confocal microscope at a magnification of 40x with both fluorescent 
and DIC settings.   
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CHAPTER 4 
 
THE ROLE OF ALDO-KETO REDUCTASE 1D1 IN PREGNANCY 
 
1. Introduction:  
The correlation between bile acid concentrations in the bile acid pool and the 
incidence of labor is of great interest.  Bile acids serves as more than biological 
detergents that aid in the emulsification and solubilization of cholesterol, dietary fats 
and lipids, they also act as hormones and are ligands for many nuclear receptors 
involved in various signaling pathways.  AKR1D1 is a 5β-reductase enzyme that is 
necessary for bile acid synthesis.  AKR1D1 is also involved in the regulation and 
metabolism of other critically important steroid hormones with known expression in 
the brain, uterus and placenta (M. Chen & Penning, 2014).  
AKR1D1 is known to be involved in the synthesis of neuroactive steroids, 
including 5β-dihydroxyprogesterone (5β-DHP) in the uterus.  Progesterone, a steroid 
hormone cholesterol derivative, is converted 5β-DHP by AKR1D1.  5β-DHP is a 
progesterone metabolite that inhibits contractions of the myometrium within the 
uterine wall during pregnancy. Therefore, during pregnancy, when estrogen levels are 
naturally higher, AKR1D1 expression must be consistently elevated in order to 
produce enough 5β-DHP to avoid pre-term uterine contractions and therefore 
premature labor (M. Chen & Penning, 2014), although the mechanism by which 5b-
DHP inhibits contractions remains unclear. Therefore, the known data indicates that 
there is a possible relationship between estrogen production and AKR1D1 expression. 
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We hypothesize that estrogen regulates AKR1D1 expression in order to help sustain a 
pregnancy by increasing AKR1D1 expression.  
 AKR1D1 expression has also been shown to decrease towards the end of 
pregnancy resulting in the initiation of labor (Byrns, 2011; Sheehan et al., 2005), 
however the mechanism by which this occurs is unclear.  This dynamic relationship 
between pregnancy and AKR1D1 can also be correlated to bile acid synthesis.  
Intrahepatic cholestasis of pregnancy (ICP) is a disorder that occurs in certain 
pregnant women during their third trimester (Geenes, 2009).  Women with ICP have a 
characteristic increase in serum bile acid due to increases in pregnancy related 
hormones, primarily estrogen.  Studies have shown that during pregnancy, expression 
of the bile salt export pump (BSEP) is significantly decreased as a result of increased 
estrogen levels (Song et al., 2014).  A decrease in BSEP expression results in an 
increase of serum bile acid levels, indicating a correlation between ICP and increased 
bile acid concentrations through altered expression of BSEP (Song et al., 2014).  Not 
only is total bile acid serum increased, but the composition of the bile acid ratio is also 
transformed.  Characteristically, women with ICP exhibit an increase in CA 
concentration. Also, women presenting with ICP have a greater likelihood of 
experiencing pre-term labor.   
 In summary, due to the knowledge that AKR1D1 expression is increased 
during pregnancy, as are estrogen levels, we hypothesize that estrogen is 
transcriptionally regulating the expression of AKR1D1 during pregnancy.  Taken 
together, investigating the expression of AKR1D1 in response to estrogen could shed 
greater light on the correlation between estrogen and the incidence of ICP.   
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2. Material and Methods: 
2.1 Treatment of HepG2 Cells 
HepG2 cells were seeded in 12-well plates at a cell density of 4 x 105 per mL in 
1 mL Phenol-Red Free DMEM supplemented with 10% (v/v) Charcoal-Stripped FBS, 
1% (v/v) penicillin/streptomycin and 1% (v/v) NEAA and cultured in a 5% CO2 
incubator overnight before treatment. After overnight incubation, cells were treated 
with 100uM E2 prepared in ethanol or a ethanol control treatment for 30 hours in 1 ml 
Phenol-Red Free DMEM supplemented with 1% Charcoal-Stripped FBS, 1% 
antibiotics and 1% NEAA. All treatments were at 0.1% of total volume medium.  
2.2 Reporter Luciferase Assay 
 HepG2 cells were seeded in 24-well plates at a cell density of 2.5 x 105 in 0.5 
mL Phenol-red Free DMEM supplemented with 10% (v/v) Charcoal Stripped FBS, 
1% (v/v) penicillin/streptomycin and 1% (v/v) NEAA and cultured in a 5% CO2 
incubator overnight before treatment. After overnight incubation, cells were treated 
transiently transfected with GenJet Version II reagent.  For all transfections, a standard 
concentration of 100ng/ul hAKR1D1 promoter reporter was used.  Additionally, 
10ng/ul null-Renilla luciferase plasmid was used as an internal control.  Nuclear 
receptor expression plasmid ERa was also transfected at 100ng/ul.  Twenty-four hours 
after transfection, cell medium was replaced with corresponding agonist treatment.  
HepG2 cells were treated with increasing concentrations of E2 prepared in ethanol or a 
control treatment of ethanol for 30 hours in 1 ml Phenol-red Free DMEM 
supplemented with 1% Charcoal-Stripped FBS, 1% antibiotics and 1% NEAA. All 
treatments were at 0.1% of total volume medium.   Following 30 hours treatment, cells 
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were washed once with phosphate-buffered saline and lysed with 100ul of 1X passive 
lysis buffer (Promega) by rocking at room temperature for 15 minutes.  Following cell 
lysis, 10ul of cell lysate was transferred into a white 96-well plate for measurement of 
luciferase activity.  A Dual-Luciferase Reporter assay system was used which 
measures the reporter vector firefly luciferase activity and subsequently the renilla 
luminesnce of the null internal control.  The luminescence signal of the reporter vector 
is normalized based on the null reading. 
2.3 HepG2 RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction 
(RT-PCR) Analysis 
Thirty hours after treatment of HepG2 cells, cells were washed twice with 1X 
PBS and homogenized by pipetting with 0.25mL RNA-Bee reagent.  Homogenates 
were then transferred to 1.5mL microcentrifuge tube.  100uL chloroform was added to 
each tube, which was then shaken vigorously for 30 seconds. The samples were then 
incubated on ice for 5 minutes before being centrifuged at 12,000 G’s for 15 minutes.  
The supernatant was then transferred to a clean microcentrifuge tube and 0.5 mL 
propanediol was added.  Samples were incubated at room temperature for 5 minutes 
and then spun at 12,000 G’s for 10 minutes.  The supernatant was discarded and the 
remaining pellet was washed with 70% ethanol in DEPC treated water and spun at 
7,500 G’s for 5 minutes.  The supernatant was then discarded and the pellet was air 
dried for 10 minutes before being reconstituted in 30 uL DEPC water.  RNA was 
quantified by nano-drop and normalized to 2ug for reverse transcription into 
complementary DNA (cDNA) (Promega).  Applied Biosystems 7500 System 
Sequence Detection Software was used for Taqman RT-PCR data analysis. Using 
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relative quantification (RQ), transcript levels of AKR1D1 were normalized against 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
2.4 HepG2 Protein Isolation and Western Blot Analysis  
HepG2 cells were washed in 1X PBS and homogenized in 
radioimmunoprecipitation assay (RIPA) buffer with 1% (v/v) protease inhibitors Halt 
and 1% (v/v) phenylmethanesulfonylfluoride (PMSF). The total cell lysate was 
homogenized by vigorous pipetting and collected into a 1.5 mL microcentrifuge tube 
to be spun at 10,000 RPM at 4°C for 10 minutes.  The supernatant was collected into a 
clean microcentrifuge tube and quantified using a standard BSA assay.  After 
quantification, samples were normalized to 10ug of HepG2 protein lysate.  A 1:1 
dilution of protein to laemilli sample buffer containing 1% (v/v) betamercaptoethanol 
was incubated at 95°C for 5 minutes, spun, and loaded into a 4-20% gradient SDS-
PAGE gel for 1 hour at 120V. Proteins were transferred from the gel using a semi-dry 
transfer apparatus onto methanol-wetted PVDF membranes at 20V for 30mins.  For 
antibody detection, membranes were blocked for 3 hours in 5% (w/v) skim milk 
dissolved into a 1X tris-buffered saline solution containing 0.05% Tween20 (1X 
TBST).  Membranes were then incubated overnight at 4°C in a 1:500 dilution of 
primary antibody in 10mL of 5% skim milk dissolved into a 1X TBST.  Membranes 
were probed for AKR1D1 (SantaCruz) or against GAPDH (SigmaAldrich).  After 
overnight incubation membranes were washed 3 times in 1X TBST and incubated 
with a corresponding 1:2000 HRP-conjugated secondary antibody for 2 hours.   
Chemiluminescent signals produced by HRP enzymes were detected using enhanced 
chemiluminescent substrates (Biorad Clarity Western ECL Substrate) and imaged 
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under a Carestream Gel Logic 2200 Pro camera for 8 minutes. Expression of protein 
was quantified and normalized against GAPDH expression.  Where possible the same 
blot was stripped and re-probed with different antibodies.   
2.5 Pregnancy Study 
Fourteen C57BL/6 female mice were bred in house and randomly separated 
into 3 groups at 6-8 weeks of age.  Five mice were separated as control mice and the 
remaining mice were bred overnight to ensure consistent timing of pregnancy. For 
mice sacrificed during pregnancy, livers were harvested at day 17 of pregnancy.  The 
remaining mice were sacrificed 3 days after giving birth.  Livers of all 14 mice were 
harvested for subsequent RNA extraction.   
2.6 Mouse Liver RNA Isolation and Quantitative Real-Time Polymerase Chain 
Reaction (RT-PCR) Analysis 
  In all mouse experiments, 100mg of mouse liver was homogenized in 1 mL 
RNA-Bee for RNA extraction.   300 uL chloroform was added to each tube, which 
was then shaken vigorously for 30 seconds. The samples were then incubated on ice 
for 5 minutes before being centrifuged at 12,000 G’s for 15 minutes.  The supernatant 
was then transferred to a clean microcentrifuge tube and 0.5 mL propanediol was 
added.  Samples were incubated at room temperature for 5 minutes and then spun at 
12,000 G’s for 10 minutes.  The supernatant was discarded and the remaining pellet 
was washed with 70% ethanol in DEPC treated water and spun at 7,500 G’s for 5 
minutes.  The supernatant was then discarded and the pellet was air dried for 10 
minutes before being reconstituted in 30 uL DEPC water.  RNA was quantified by 
nano-drop and normalized to 2ug for reverse transcription into complementary DNA 
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(cDNA) (Promega).  Applied Biosystems 7500 System Sequence Detection Software 
was used for Taqman RT-PCR data analysis. Applied Biosystems 7500 System 
Sequence Detection Software was used for Taqman RT-PCR data analysis. Using 
relative quantification (RQ), transcript levels of AKR1D1 were normalized against 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).   
2.7 Statistical Analysis 
A Student’s t-test was applied to pairwise comparison for normally distributed data.  P 
0.05 or lower was considered statistically significant.   
3. Results 
3.1 Altered endogenous AKR1D1 expression in estrogen treated HepG2 cells.   
 AKR1D1 is most abundantly expressed in the liver; therefore we examined the 
effects of estrogen on hepatic AKR1D1 expression in HepG2 cells.  HepG2 cells were 
seeded in phenol-red free medium supplemented with charcoal stripped FBS in order 
to limit exogenous estrogenic effects, and thus, false positive results.  Cells were 
treated with estrogen and isolated for RNA and protein analysis.  As seen in Figure 
23A, RT-PCR data reveals that AKR1D1 showed an increased trend in expression 
with E2 treatment (results not significant).  Protein data (Figure 23B) revealed that 
endogenous AKR1D1 expression was significantly increased with treatment of 
estrogen (p < .01).  
3.2 Estrogen mediated transactivation of the human AKR1D1 promoter.    
 With confirmation that endogenous hepatic AKR1D1 expression was altered 
with estrogen treatment, we next investigated the activity of the AKR1D1 promoter in 
response to estrogen in-vitro.  The human AKR1D1 promoter reporter, phAKR1D1 (-
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5.0 kb) was transiently transfected with estrogen receptor alpha (ERα) into HepG2 
cells.  Twenty-four hours after transfection cells were treated with 100nM estrogen.  
Thirty hours after treatment, luciferase activity of AKR1D1 was quantified.  As shown 
in Figure 24, while no significant change was observed on the AKR1D1 promoter in 
the absence of the ERα nuclear receptor, the presence of ERα significantly increased 
the expression of the human AKR1D1 promoter reporter (p < .01) as compared to 
DMSO. The results indicate the possible presence of a previously unidentified 
estrogen response element (ERE) on the promoter region of AKR1D1, which is 
resulting in the transactivation of AKR1D1 expression.  
3.3 AKR1D1 is dose-dependently regulated by estrogen.  
 With confirmation of the ERE on the 5.0kb human AKR1D1 promoter, we 
next investigated the effect of various concentrations of estrogen on AKR1D1 
expression in-vitro.  HepG2 cells were co-transfected with phAKR1D1 (-5.0 kb) and 
ERα and treated with increasing concentrations of estrogen for 30 hours.  As seen in 
Figure 25, AKR1D1 expression is altered in response to different concentrations of 
estrogen.  The results indicate that AKR1D1 expression peaks at 40nM E2 and 400nM 
E2 and decreases with 80nM E2 and over 1ug E2 treatment in-vitro.  While a 
definitive trend has not yet been established, the data suggests a highly dynamic 
relationship between AKR1D1 and estrogen.   
3.4  Hepatic AKR1D1 Expression is Up-Regulated During Pregnancy  
 It is well established that AKR1D1 catalyzes the conversion of progesterone 
into its metabolite 5b-DHP in order to inhibit contractions and maintain normal 
pregnancy conditions. In late stages of pregnancy the production of 5b-DHP is 
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decreased which results in an initiation of contractions and ultimately, labor.  To 
examine this phenomenon in-vivo, mice were separated into 3 groups and livers were 
harvested for RNA and protein before, during and after pregnancy.  As seen in Figure 
26A, the results indicate that transcriptionally, AKR1D1 expression is significantly 
increased during pregnancy by over eight fold as compared to mice that are not 
pregnant.  The expression of AKR1D1 decreases directly after birth, presumably 
returning back to control level over time.  Translationally, AKR1D1 exhibits a trend 
similar to that seen in RNA expression, however the results are not significant (Figure 
26B).  While the role of AKR1D1 expression during pregnancy has been documented 
within the uterus, our data now clearly demonstrates that AKR1D1 expression within 
the liver is also altered during pregnancy.    
4. DISCUSSION 
 While AKR1D1 is necessary for the synthesis of primary bile acids it is also 
involved in steroid metabolism. AKR1D1 plays a vital role in the metabolism of 
progesterone to its metabolite, 5β-dihydroxyprogesterone (5β-DHP). The role of 5β-
DHP is in prevention of uterine contractions during pregnancy.  AKR1D1 expression 
must be maintained at elevated levels during pregnancy in order to produce sufficient 
concentrations of the progesterone metabolite to prevent uterine contractions prior to 
parturition.  Towards the end of pregnancy, AKR1D1 expression dramatically 
declines, reducing the expression of 5β-DHP and resulting in a relaxing of the uterine 
muscle where contractions begin to initiate labor (Byrns, 2011; Sheehan et al., 2005).  
Ultimately, the relationship between estrogen and AKR1D1 expression is poorly 
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defined therefore mechanism by which AKR1D1 expression is increased during 
pregnancy and dramatically reduced prior to labor is not clearly understood.  
 To examine the effects of pregnancy on the expression of AKR1D1 in-vivo, 
AKR1D1 expression was measured in mice before, during and after pregnancy.  Our 
results indicate that AKR1D1 expression is increased in mice during pregnancy and is 
decreased after birth in-vivo. After investigation of the endogenous expression of 
AKR1D1 in response to estrogen in-vitro, we were able to confirm our hypothesis that 
estrogen increases AKR1D1 expression.  This would explain the increased AKR1D1 
expression in our animal study as well as the increase in AKR1D1 expression 
necessary for a full term pregnancy.  It is well known that during pregnancy estrogen 
levels are elevated (Pařízek et al., 2014).  For the first time, our results indicate that it 
may be through increased estrogen levels during pregnancy that regulate the 
expression of AKR1D1 in order to produce 5β-DHP and prevent contractions.  To 
further understand the transcriptional regulation of AKR1D1 by estrogen, phAKR1D1 
(-5.0 kb) promoter reporter was co-transfected with ERα and treated with estrogen.  
For the first time we were able to reveal the possible presence of a previously un-
identified estrogen response element (ERE) within the 5.0 kb AKR1D1 promoter 
region.  Due to the fact that initial testing of the ERE on AKR1D1 in response to 
estrogen was under elevated concentrations of estrogen at 100nM, we next examined 
if the expression of AKR1D1 in response to estrogen was dose-dependent.  Our results 
revealed a highly complex and dynamic relationship between AKR1D1 and estrogen.  
While even the smallest concentrations of estrogen up-regulate AKR1D1 promoter 
activity, increased concentrations varied with altered expression.  The intricate 
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alterations in AKR1D1 expression in response to varying concentrations of estrogen 
paint the picture of an atypical dose response curve.  The initial peak illustrated in 
Figure 25 may represent changes in AKR1D1 expression under physiologically 
normal concentrations of estrogen while the second peak may represent more 
pathological circumstances. Overall, the relationship between AKR1D1 and estrogen 
depicted in Figure 25 may correlate to the fluctuating concentrations exhibited during 
normal pregnancy.   
It has been suggested that excessively high estrogen levels are what ultimately 
inhibits the conversion of progesterone to 5β-DHP by AKR1D1 (Byrns, 2011). Since 
our data revealed a decreased trend at high concentrations but not a decrease as 
compared to the control, it can be speculated that changes in AKR1D1 expression 
towards the end of pregnancy may be dependent on a number of other factors as well. 
It can be considered that any number of hormones, which are increased during 
pregnancy, may be competing with estrogen binding on the AKR1D1 promoter.   
Estrogen receptors are highly promiscuous with respect to ligand selectivity (Ng, 
Perkins, Tong, & Hong, 2014) and therefore the binding of a hormone which could 
compete with estrogen may result in a decrease of AKR1D1 expression and therefore 
a decrease of the 5β-DHP metabolite. Furthermore, it is possible that elevated 
concentrations of estrogen do, in fact, decrease AKR1D1 expression prior to 
parturition, however the specific element responsible for the decrease is located on a 
region beyond the 5.0kb region that has been cloned. Currently, further testing of 
additional pregnancy related hormones on an extended promoter region is necessary 
prior to understanding the decrease in AKR1D1 prior to parturition.    
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In summary, our data collectively demonstrates that AKR1D1 is 
transcriptionally regulated by estrogen through a previously un-identified estrogen 
response element within the 5.0 kb promoter region.  The increase in AKR1D1 
expression in response to estrogen serves to fill the gap in knowledge pertaining to the 
elevated AKR1D1 expression necessary to maintain pregnancy.  As hormone levels 
are increased during pregnancy, estrogen serves to increase AKR1D1 expression in 
order to sufficiently catalyze the conversion of progesterone to 5β-DHP to prevent 
uterine contractions. With the identification of an estrogen response element on the 
AKR1D1 promoter and the known promiscuity of the estrogen receptor ligand 
selectivity, further testing on AKR1D1 expression is necessary in order to identify the 
mechanism by which AKR1D1 expression is substantially decreased prior to 
parturition.  Furthermore, with enhanced understanding of the relationship between 
estrogen and AKR1D1, a link may be established between AKR1D1 and ICP in order 
to fully understand the role of AKR1D1 in pregnancy.   
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Figure 23.  Estrogen up-regulates AKR1D1 expression in-vitro in HepG2 cells.   
HepG2 cells were treated with 100uM E2 or an EtOH negative control for 30 hours 
prior to RNA and protein extractions.  A. RT-PCR analysis of AKR1D1 expression in 
response to estrogen treatment.  B.  Western blot analysis of AKR1D1 expression in 
response to estrogen treatment.  The data are presented as a fold change in relative 
expression of the mean of 3 replicates as compared to the negative control and a p < 
.05 was considered significant (Student’s t-test).   
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Figure 24. Alteration of human AKR1D1 promoter reporter expression with E2 
treatment in HepG2 Cells with or without ERα.   
 
HepG2 cells were transiently transfected with the human AKR1D1 promoter reporter 
plasmid phAKR1D1 (-5.0 kb) with or without co-transfection of ERα and treated with 
estrogen for 30 hours.  Luciferase activation was measured by a dual-luciferase 
reporter assay system. The data are presented as a fold change in relative expression of 
the mean of 3 replicates as compared to the negative control and a p < 0.05 was 
considered significant (Student’s t-test).   
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Figure 25. Alteration of human AKR1D1 promoter reporter expression with 
increasing E2 treatment in HepG2 Cells with or without ERα.   
 
HepG2 cells were transiently transfected with the human AKR1D1 promoter reporter 
plasmid phAKR1D1 (-5.0 kb) and ERα and treated with increasing concentrations of 
estrogen for 30 hours.  Luciferase activation was measured by a dual-luciferase 
reporter assay system. The data are presented as a fold change in relative expression of 
the mean of 3 replicates as compared to the negative control and a p < 0.05 was 
considered significant (Student’s t-test).   
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Figure 26. Altered AKR1D1 expression, before, during and after pregnancy.  
 
Female mice were separated into 3 groups (6 mice per group) before, during and after 
pregnancy for liver isolation.  RNA and Protein expression of AKR1D1 was 
measured.  (A) RNA was isolated from the liver for RT-PCR quantification.  
AKR1D1 RNA expression was normalized against GAPDH.  The data are presented 
as a fold change in relative expression of the mean of 5 replicates as compared to the 
negative control and a p < .05 was considered significant (student t-test).  (B) Protein 
expression of endogenous AKR1D1 was detected and quantified by western blot.  The 
data are presented as a fold change in relative expression of the mean of 5 replicates as 
compared to the negative control and a p < .05 was considered significant (Student’s t-
test).   
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CHAPTER 5 
 
SUMMARY 
 
The maintenance of cholesterol and bile acid levels are critical for the 
prevention of cardiovascular and metabolic diseases. Bile acids are the end product of 
cholesterol catabolism and serve to solubilize, transport and eliminate cholesterol, 
lipids and fat-soluble vitamins from the liver and intestines.  Recently it has been 
discovered that the role of bile acids is greater than to serve as biological detergents 
and emulsifiers, but are also to serve as intricate signaling hormones responsible for 
the regulation of numerous metabolic and regulatory processes such as lipid, drug, and 
glucose metabolism. Impairment in the efficacy of bile acid signaling could lead to the 
occurrence or exacerbation of adverse metabolic disorders including obesity, diabetes, 
cholestasis, or liver injury, cancer and even pre-term birth in pregnant women. 
 One underlying trend that is seen in many bile acid related cardiovascular, 
metabolic and gestational disorders is an imbalance in the bile acid pool composition 
and size.  Depending on the concentrations of individual bile acids, the total bile acid 
pool composition can be either hydrophobic or hydrophilic in nature.  The ratio of 
hydrophobic to hydrophilic bile acids in the bile acid pool greatly affects rates of 
absorption and excretion, and therefore the concentrations must be tightly regulated.  
The size of the bile acid pool must also be regulated because while at physiological 
concentrations bile acids are not harmful to the body, due to their detergent-like 
properties, bile acid accumulation can be toxic. Deregulation of bile acid synthesis 
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could lead to changes in bile acid pool composition or size may lead to pathological 
consequences although little is known regarding the underlying mechanisms in 
physiological and pathological conditions.  
The objective of these studies was to investigate the regulation of bile acid 
synthesis with respect to aldo-keto reductase 1D1 (AKR1D1), a 5β-reductase enzyme 
responsible for the synthesis of the hydrophobic primary bile acid, chenodeoxycholic 
acid (CDCA).  We will also examined 12-alpha hydroxylase (CYP8B1), the enzyme 
responsible for the production of the hydrophilic bile acid, cholic acid (CA).  While it 
is understood that AKR1D1 is responsible for the production of CDCA, and CYP8B1 
is responsible for the production of CA, little is known regarding their individual 
regulation. Likewise, little is known regarding their roles in regards to the regulation 
and maintenance of the CDCA to CA composition ratio.  To date, much attention has 
been given to CYP8B1 expression with claims that CYP8B1 is the rate-limiting 
enzyme for the production of either CDCA or CA.  It can be argued that since 
AKR1D1 is responsible for the production of CDCA, and CDCA is the more toxic 
bile acid, which has the potential to cause or exacerbate pathological outcomes, insight 
into the regulation of AKR1D1 is vital. Furthermore, due to the characteristic 
involvement of AKR1D1 in the synthesis of steroid hormones, such as progesterone, 
additional understanding of the contribution of AKR1D1 in processes such as 
pregnancy and disorders such as intrahepatic cholestasis of pregnancy is fundamental.   
 Understanding the physiological mechanisms by which AKR1D1 regulates 
CDCA synthesis, and likewise, CDCA regulates AKR1D1 synthesis, will ultimately 
reveal a more in-depth understanding of the regulation of the bile acid synthesis 
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pathway. Additionally, in understanding the regulation of the bile acid synthesis 
pathway, which generates both hydrophobic and hydrophilic bile acids, novel 
mechanistic signaling pathways may be revealed in which the ratio of bile acid’s 
composition may be controlled to treat and prevent cardiovascular and metabolic 
disorders.  
In this dissertation, we first provided an overall summary characterizing the 
role of cholesterol and bile acid and the association between them that is essential for 
normal liver function.  Within this summary of current knowledge pertaining to bile 
acid synthesis and homeostasis was an introduction of key enzymes that are involved 
in the formation of primary bile acids, mainly, AKR1D1 and CYP8B1 as well as 
certain essential nuclear receptors and signaling pathways. Next, we investigated the 
regulation of AKR1D1 by primary bile acids, CDCA and CA, and identified possible 
signaling pathways that may be associated, responsible or manipulated for such 
regulation.  We then examined the role of AKR1D1 in conditions of metabolic disease 
and liver cancer and introduced findings that are related to further understanding the 
role of AKR1D1 in physiological and pathological conditions. Finally, we investigated 
the role of AKR1D1 during pregnancy. 
 Within the combined research is data demonstrating the role and regulation of 
AKR1D1 in physiological and pathological conditions ranging from bile acid 
synthesis, steroid metabolism and various diseases and disorders.  Our data exposes 
various possible mechanisms by which AKR1D1 expression is regulated through bile 
acid and various signaling pathways.  Specifically, the regulation of AKR1D1 by 
CDCA and CA was established.  This phenomenon confirms that the liver is 
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consistently altering AKR1D1 expression in an effort to control the synthesis of 
CDCA or CA in order to maintain physiologically normal bile acid concentrations 
within the bile acid pool.  By doing this, AKR1D1, and not CYP8B1, may be 
responsible for the regulation of the CDCA to CA ratio and ultimately the 
hydrophobicity or hydrophilicity of the bile acid pool.  
Additionally, for the first time, the possible presence of various response 
elements were identified within the promoter region of the human AKR1D1 gene, 5kb 
upstream from the start of transcription.  Within the promoter region exist possible 
response elements for PPAR, LXR and ER.  Isoforms of PPAR bind the PPAR 
response element on the AKR1D1 promoter and under agonist activation represses the 
transcription of AKR1D1 resulting in a decrease of gene expression.  On the other 
hand, LXRβ binds the LXR response element on the AKR1D1 promoter region and 
under activation by LXR agonist’s increases the transcription of AKR1D1.  Likewise, 
ERα binds the estrogen response element on the AKR1D1 promoter region and in 
response to estrogen increases AKR1D1 expression.  The suggested presence of these 
previously un-identified response elements expose novel pathways by which AKR1D1 
expression can be regulated and manipulated to control bile acid synthesis.   
Moreover, the data presented in this dissertation serves to fill in gaps of 
knowledge pertaining to the occurrence or exacerbation of bile acid related metabolic 
disorders and cancer.  The decrease in AKR1D1 expression that was observed in 
diabetic patients serves to explain the decrease in CDCA expression in diabetic livers.  
We propose that this decrease represents a mechanism by which the liver alters 
AKR1D1 expression in an effort to protect the liver from further toxicity in the 
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presence of CDCA and assist the liver in regaining physiological control of bile acid 
concentrations.  Similarly, while it is known that an accumulation of bile acids can 
result in hepatocyte inflammation, damage and the progression of HCC, our results 
indicate that HCC patients presented with a decrease in AKR1D1 expression.  We 
theorize that this decrease is a hepato-protective mechanism by which AKR1D1 
expression is altered to minimize CDCA production in an already diseased liver.   
Finally, our experiments examined the role of AKR1D1 in response to 
estrogen.  Our results indicate that AKR1D1 expression is increased during pregnancy, 
possibly through activation of the estrogen response element located on the promoter 
region of AKR1D1 and decreased towards the end prior to labor.  These results are 
consistent with the knowledge that elevated AKR1D1 expression is required in order 
to catalyze the production of the progesterone metabolite necessary to prevent uterine 
contractions. Furthermore our results uncovered the possible existence of a previously 
un-identified estrogen response element on the promoter region of AKR1D1.  Our data 
demonstrates a highly complex relationship between AKR1D1 and estrogen.  
In conclusion, the presented data represents a comprehensive understanding of 
the transcriptional regulation of the 5β-reductase enzyme, AKR1D1.  Within this 
dissertation we expose novel mechanism and pathways by which AKR1D1 may be 
regulated in physiological, as well as pathological, conditions.   The evidence provided 
suggests that the liver is consistently attempting to maintain bile acid homeostasis 
through altered expression of AKR1D1. Furthermore, we have laid the foundation for 
future manipulation of AKR1D1 expression in order to regulate the bile acid pool ratio 
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to therapeutically alleviate or prevent various bile acid and steroid related disorders 
and diseases.  
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